[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 318
1. Medina EA, Arias VL: [Middle ear adenoma]. Biomedica; 2009 Sep;29(3):348-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Herein, a middle ear neoplasm is described that became apparent because of its appearance in the external ear duct as it protruded from the middle ear through the eardrum.
  • Following resection, the specimen was determined to be a benign epithelial tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20436986.001).
  • [ISSN] 0120-4157
  • [Journal-full-title] Biomédica : revista del Instituto Nacional de Salud
  • [ISO-abbreviation] Biomedica
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Colombia
  •  go-up   go-down


2. Patraki E, Cardillo MR: Quantitative immunohistochemical analysis of matrilysin 1 (MMP-7) in various renal cell carcinoma subtypes. Int J Immunopathol Pharmacol; 2007 Oct-Dec;20(4):697-705
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study we investigated differential expression of MMP-7 in the epithelium and stroma of 95 paraffin-embedded renal tumor samples by immunohistochemistry and compared tumoral with normal peritumoral renal tissue.
  • We also determined a possible correlation of the immunohistochemical findings with histological subtype, tumor grade and stage of RCC.
  • In all areas examined MMP-7 protein expression was significantly higher in epithelium than in stroma (P less than 0.01).
  • MMP-7 was more less expressed in peritumoral normal areas than in benign epithelial neoplasias (renal papillary and oncocytomas) and RCC carcinomas, reaching the highest immunopositive reaction in chromophobe RCC subtypes, followed by conventional clear-cell and chromophilic-papillary RCC histological subtypes and the lowest levels in more aggressive RCC histotypes (spindle-cell and collecting-duct RCCs).
  • [MeSH-minor] Aged. Aged, 80 and over. Epithelial Cells / drug effects. Epithelial Cells / metabolism. Female. Humans. Image Processing, Computer-Assisted. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis / pathology. Paraffin Embedding. Stromal Cells / drug effects. Stromal Cells / metabolism. Tissue Fixation

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18179742.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


3. Sakai H, Mori T, Iida T, Tokuma Y, Maruo K, Masegi T: Immunohistochemical features of proliferative marker and basement membrane components of two feline inductive odontogenic tumours. J Feline Med Surg; 2008 Jul;10(3):296-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical features of proliferative marker and basement membrane components of two feline inductive odontogenic tumours.
  • Feline inductive odontogenic tumour (FIOT) is a rare and interesting odontogenic neoplasm in which the odontogenic epithelium has inductive potential to form aggregated foci of dental pulp-like mesenchymal cells.
  • Histopathologically, the masses consisted of non-encapsulated invasive neoplasms exhibiting proliferation of epithelial and mesenchymal components with local infiltration into the maxillary bone in both cases.
  • The epithelial component formed islands, anastomosing strands, and solid sheets of polygonal epithelial cells.
  • Type IV collagen and laminin were constantly positive around the foci of epithelial cells, and Ki-67 positive indices were extremely low; therefore, these findings consistent with the benign clinical presentation of FIOT.
  • [MeSH-major] Cat Diseases / diagnosis. Cat Diseases / immunology. Mandibular Neoplasms / veterinary. Odontogenic Tumors / veterinary

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17766158.001).
  • [ISSN] 1098-612X
  • [Journal-full-title] Journal of feline medicine and surgery
  • [ISO-abbreviation] J. Feline Med. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Collagen Type IV; 0 / Ki-67 Antigen
  •  go-up   go-down


Advertisement
4. Starost MF: Adenomyofibroma of the fimbria in a cynomolgus monkey (Macaca fascicularis). J Vet Diagn Invest; 2009 Nov;21(6):892-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Microscopically, the mass was composed of large, plump, finger-like projections lined primarily by simple columnar ciliated epithelium.
  • This benign neoplasm should be considered as a differential diagnosis for masses arising from the fallopian tube in old-world macaques.
  • [MeSH-major] Adenofibroma / veterinary. Monkey Diseases / pathology
  • [MeSH-minor] Animals. Animals, Laboratory. Diagnosis, Differential. Dog Diseases / pathology. Dogs. Female. Genitalia, Female / pathology. Macaca fascicularis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19901298.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


5. Karim RZ, Gerega SK, Yang YH, Horvath L, Spillane A, Carmalt H, Scolyer RA, Lee CS: Proteins from the Wnt pathway are involved in the pathogenesis and progression of mammary phyllodes tumours. J Clin Pathol; 2009 Nov;62(11):1016-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteins from the Wnt pathway are involved in the pathogenesis and progression of mammary phyllodes tumours.
  • BACKGROUND: The Wnt pathway is important in cell signalling transduction and is involved in the pathogenesis of multiple tumour types.
  • A comprehensive analysis of the expression of Wnt signalling pathway proteins in mammary phyllodes tumours (PTs) has not been previously performed.
  • AIMS: To evaluate the immunohistochemical expression of Wnt pathway proteins in a cohort of PTs, to determine their role in tumour pathogenesis and to identify any associations with patient outcome.
  • METHODS: 65 PTs (34 benign, 23 borderline and 8 malignant) diagnosed at a single institution between 1990 and 2006 were analysed.
  • Stroma and epithelium were scored separately.
  • Epithelial membranous and stromal nuclear beta-catenin, epithelial cytoplasmic Wnt1 and epithelial E-cadherin all also showed increasing expression with increasing tumour grade, however, the differences were not significant.
  • Disease-free survival was significantly decreased (p = 0.0017) with positive epithelial E-cadherin staining.
  • CONCLUSIONS: Results suggest that alterations in the Wnt pathway are important in the progression and in the epithelial and stromal interactions in PTs.
  • They have important implications for understanding the pathogenesis of these uncommon but clinically important tumours.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. Phyllodes Tumor / metabolism. Wnt Proteins / metabolism
  • [MeSH-minor] Cadherins / metabolism. Cohort Studies. Disease Progression. Female. Humans. Neoplasm Proteins / metabolism. Proto-Oncogene Proteins / metabolism. Signal Transduction / physiology. Survival Analysis. Tissue Array Analysis / methods. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19861560.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins; 0 / SFRP4 protein, human; 0 / Wnt Proteins; 0 / beta Catenin
  •  go-up   go-down


6. Bornstein MM, Filippi A, Altermatt HJ, Lambrecht JT, Buser D: [The odontogenic keratocyst--odontogenic cyst or benign tumor?]. Schweiz Monatsschr Zahnmed; 2005;115(2):110-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The odontogenic keratocyst--odontogenic cyst or benign tumor?].
  • [Transliterated title] Die odontogene Keratozyste--odontogene Zyste oder benigner Tumor?
  • Besides a predilection for recurrence, the keratocysts, in contrast to other odontogenic cysts, show a more aggressive clinical behavior and demonstrate a high mitotic count and higher turnover rate of the epithelium.
  • This led to the tentative suggestion that the keratocyst might be a benign cystic neoplasm rather than simply an odontogenic cyst.

  • MedlinePlus Health Information. consumer health - Jaw Injuries and Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771334.001).
  • [ISSN] 0256-2855
  • [Journal-full-title] Schweizer Monatsschrift fur Zahnmedizin = Revue mensuelle suisse d'odonto-stomatologie = Rivista mensile svizzera di odontologia e stomatologia
  • [ISO-abbreviation] Schweiz Monatsschr Zahnmed
  • [Language] FRE; GER
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 68238-35-7 / Keratins
  • [Number-of-references] 69
  •  go-up   go-down


7. Hu Y, Rosen DG, Zhou Y, Feng L, Yang G, Liu J, Huang P: Mitochondrial manganese-superoxide dismutase expression in ovarian cancer: role in cell proliferation and response to oxidative stress. J Biol Chem; 2005 Nov 25;280(47):39485-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The manganese-containing SOD (Mn-SOD) has been suggested to have tumor suppressor function and is located in the mitochondria where the majority of O(2)(-) is generated during respiration.
  • The present study used a human tissue microarray to analyze Mn-SOD expression in primary ovarian cancer tissues, benign ovarian lesions, and normal ovary epithelium.
  • In experimental systems, suppression of Mn-SOD expression by small interfering RNA caused a 70% increase of superoxide in ovarian cancer cells, leading to stimulation of cell proliferation in vitro and more aggressive tumor growth in vivo.
  • [MeSH-minor] Animals. Base Sequence. Cell Line, Tumor. Cell Proliferation. Cystadenoma / enzymology. Cystadenoma / genetics. Cystadenoma / pathology. Female. Gene Expression Profiling. Humans. Mice. Mitochondria / enzymology. Oligonucleotide Array Sequence Analysis. Ovary / cytology. Ovary / enzymology. Oxidative Stress. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. RNA, Small Interfering / genetics. Transfection

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16179351.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA100428; United States / NCI NIH HHS / CA / CA109041; United States / NCI NIH HHS / CA / CA85563
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / RNA, Small Interfering; EC 1.15.1.1 / Superoxide Dismutase
  •  go-up   go-down


8. Bernard JE, Butler MO, Sandweiss L, Weidner N: Anal intraepithelial neoplasia: correlation of grade with p16INK4a immunohistochemistry and HPV in situ hybridization. Appl Immunohistochem Mol Morphol; 2008 May;16(3):215-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Accurate diagnosis and grading of anal intraepithelial neoplasia (AIN) can be problematic, especially in separating AIN from anal transitional-zone epithelium.
  • To investigate if p16 would help in more accurately diagnosing and grading AIN, particularly when attempting to distinguish benign transitional-zone epithelium from high-grade AIN, we separately assessed these stains in a blinded manner on a large number of consecutive anal biopsies and anal tissues and correlated the findings with the diagnosis and grade of AIN.
  • Of interest, 30 cases were negative for AIN and p16 staining and of these, 2 (7%) were positive for HPV (both LR subtype).
  • We conclude that the correlation between AIN and p16 and HPV is strong enough to be quite useful in distinguishing true AIN from benign mimics, such as benign transitional-zone epithelium.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18301250.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA Probes, HPV
  •  go-up   go-down


9. Marocchio LS, Júnior DS, de Sousa SC, Fabre RF, Raitz R: Multifocal diffuse oral melanoacanthoma: a case report. J Oral Sci; 2009 Sep;51(3):463-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oral melanoacanthoma (OMA) is a rare benign lesion characterized by colonization of acanthotic epithelium by dendritic melanocytes.
  • [MeSH-minor] Aged. Female. Humans. Melanocytes / pathology. Mouth Mucosa / pathology. Neoplasm Regression, Spontaneous

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19776516.001).
  • [ISSN] 1880-4926
  • [Journal-full-title] Journal of oral science
  • [ISO-abbreviation] J Oral Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Qin X, Liu F: The clinicopathologic features of intraductal papillary mucinous neoplasms of the pancreas. Front Med China; 2007 May;1(2):121-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since first described in 1982, intraductal papillary mucinous neoplasm (IPMN) has been the preferred term to describe the proliferation of the pancreatic ductal epithelium.
  • Most branch duct IPMNs are benign, whereas the other two types are often malignant.
  • The prognosis is more favorable after complete resection of benign and non-invasive malignant IPMNs.
  • On the other hand, asymptomatic branch duct IPMNs without mural nodules can be observed without the need for resection for a considerable period of time.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2000 Feb;95(2):441-5 [10685747.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Gut. 2002 Nov;51(5):717-22 [12377813.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Surgery. 1997 Sep;122(3):617-25 [9308621.001]
  • [Cites] AJR Am J Roentgenol. 2000 May;174(5):1403-8 [10789803.001]
  • [Cites] J Comput Assist Tomogr. 1999 Mar-Apr;23 (2):301-5 [10096342.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] Pancreatology. 2001;1(6):633-6 [12120246.001]
  • [Cites] Gastroenterology. 1991 Aug;101(2):512-9 [1648527.001]
  • [Cites] Cancer. 1992 Mar 15;69(6):1327-33 [1540869.001]
  • [Cites] Am J Surg. 2005 May;189(5):632-6; discussion 637 [15862510.001]
  • [Cites] Arch Surg. 2001 Nov;136(11):1256-62 [11695969.001]
  • [Cites] Gastrointest Endosc. 1998 Jan;47(1):42-9 [9468422.001]
  • [Cites] Surg Oncol. 2004 Jul;13(1):27-39 [15145031.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):313-21; discussion 321-2 [11524584.001]
  • [Cites] Arch Surg. 2003 Jun;138(6):610-7; discussion 617-8 [12799331.001]
  • [Cites] Ann Surg. 1998 Nov;228(5):685-91 [9833807.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(2):147-55 [14505148.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):62-77 [11815961.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):376-81 [11260102.001]
  • [Cites] J Gastroenterol. 2005 Jul;40(7):669-75 [16082582.001]
  • [Cites] Endoscopy. 2000 Jun;32(6):472-6 [10863915.001]
  • [Cites] Am J Surg. 1998 May;175(5):426-32 [9600293.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] Am J Gastroenterol. 2001 May;96(5):1429-34 [11374678.001]
  • [Cites] Surgery. 2001 Jan;129(1):55-65 [11150034.001]
  • [Cites] Am J Surg. 2003 Mar;185(3):251-5 [12620565.001]
  • [Cites] Hepatogastroenterology. 1996 May-Jun;43(9):692-709 [8799417.001]
  • (PMID = 24557662.001).
  • [ISSN] 1673-7342
  • [Journal-full-title] Frontiers of medicine in China
  • [ISO-abbreviation] Front Med China
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


11. Chechlinska M, Kowalewska M, Brzoska-Wojtowicz E, Radziszewski J, Ptaszynski K, Rys J, Kaminska J, Nowak R: Squamous cell carcinoma antigen 1 and 2 expression in cultured normal peripheral blood mononuclear cells and in vulvar squamous cell carcinoma. Tumour Biol; 2010 Dec;31(6):559-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Serum levels of SCCA are elevated in patients with benign skin diseases and in patients with SCC.
  • High SCCA concentrations were found in vulvar tumours and in metastatic lymph nodes, while negative inguinal lymph nodes from the same patients often presented significantly less SCCA.
  • SCCA expression level in normal PBMC is much lower than in the squamous epithelium-derived cells.
  • In VSCC, in addition to tumour itself, metastatic lymph nodes seem also to be a potential source of serum SCCA.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Carcinoma, Squamous Cell / metabolism. Leukocytes, Mononuclear / metabolism. Serpins / metabolism. Vulvar Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cell Line, Tumor. Cells, Cultured. Female. Humans. RNA, Messenger / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2006 Nov;42(16):2671-4 [16978860.001]
  • [Cites] Tumour Biol. 2006;27(3):142-52 [16641548.001]
  • [Cites] FEBS Lett. 2007 Sep 4;581(22):4260-4 [17707374.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Apr;66(1):10-20 [17964182.001]
  • [Cites] Nat Rev Cancer. 2010 Jan;10(1):2-3 [20050335.001]
  • [Cites] J Gene Med. 2010 Jun;12(6):545-54 [20527047.001]
  • [Cites] J Histochem Cytochem. 2000 Jan;48(1):113-22 [10653592.001]
  • [Cites] Int J Cancer. 2000 Jul 20;89(4):368-77 [10956412.001]
  • [Cites] Oncol Rep. 2001 Mar-Apr;8(2):347-54 [11182054.001]
  • [Cites] Int J Cancer. 2001 Jan 20;95(1):39-43 [11241309.001]
  • [Cites] Cancer Lett. 2001 Jun 26;167(2):205-13 [11369142.001]
  • [Cites] Eur J Cancer. 2002 Oct;38(15):1987-91 [12376202.001]
  • [Cites] J Reprod Med. 2002 Sep;47(9):718-20 [12380452.001]
  • [Cites] Cytokine. 2002 Sep 21;19(6):287-96 [12421571.001]
  • [Cites] Neoplasma. 2004;51(2):103-9 [15190419.001]
  • [Cites] Cancer. 1977 Oct;40(4):1621-8 [332328.001]
  • [Cites] J Cell Biol. 1988 Mar;106(3):761-71 [2450098.001]
  • [Cites] Cancer. 1989 Oct 15;64(8):1652-6 [2790678.001]
  • [Cites] Gynecol Oncol. 1989 Nov;35(2):227-32 [2807015.001]
  • [Cites] Clin Chem. 1990 Feb;36(2):251-4 [2302769.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Nov 27;181(1):51-8 [1958219.001]
  • [Cites] Cancer. 1990 Oct 1;66(7):1505-12 [2208001.001]
  • [Cites] J Am Acad Dermatol. 1990 Apr;22(4):639-42 [2319025.001]
  • [Cites] Chest. 1994 Mar;105(3):773-6 [8131539.001]
  • [Cites] J Dermatol. 1994 Feb;21(2):67-72 [8182213.001]
  • [Cites] Cancer. 1995 Sep 1;76(5):758-64 [8625177.001]
  • [Cites] Tumour Biol. 1996;17(2):81-9 [8658017.001]
  • [Cites] J Biol Chem. 1997 Jan 17;272(3):1849-55 [8999871.001]
  • [Cites] Int J Cancer. 1997 Feb 20;74(1):75-80 [9036873.001]
  • [Cites] Biochemistry. 1998 Apr 14;37(15):5258-66 [9548757.001]
  • [Cites] Tumour Biol. 1998;19(6):517-26 [9817981.001]
  • [Cites] Int J Cancer. 1999 Oct 8;83(2):167-70 [10471522.001]
  • [Cites] J Biol Chem. 2005 Mar 18;280(11):9761-4 [15677460.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):904-7 [15894354.001]
  • [Cites] Clin Exp Allergy. 2005 Oct;35(10):1327-33 [16238792.001]
  • [Cites] Int J Gynecol Cancer. 2007 Jan-Feb;17(1):174-81 [17291250.001]
  • (PMID = 20589490.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Serpins; 0 / squamous cell carcinoma-related antigen
  • [Other-IDs] NLM/ PMC2953620
  •  go-up   go-down


12. Kushida Y, Haba R, Kadota K, Doi T, Ishikawa M, Hirakawa E, Kira M: Composite mucinous and granulosa cell tumor of the ovary. Pathol Int; 2005 Dec;55(12):797-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite mucinous and granulosa cell tumor of the ovary.
  • A composite mucinous and granulosa cell tumor of the ovary in a 76-year-old woman is herein reported.
  • At laparotomy this tumor proved to be a solid and cystic mass measuring 10 cm in greatest diameter.
  • Many of the cysts were lined with a benign mucinous epithelium of the endocervical type, and solid areas contained a proliferation of granulosa cells.
  • A theca cell component was also present in areas adjacent to the mucinous epithelium.
  • The coexistence of mucinous and granulosa cell tumor is extremely rare and only four such cases have previously been reported in the literature, and the histogenesis of this tumor has not yet been elucidated.
  • In the present case it is suggested that the granulosa cell element commenced as a reactive stromal hyperplasia in the wall of the pre-existing mucinous neoplasm and thereafter progressed to the point of producing a tumor-like mass or neoplastic changes.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Granulosa Cell Tumor / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16287496.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


13. Wang XY, Xu SJ, Li XG: Post-operative implantation metastasis of craniopharyngioma: a case report. J Int Med Res; 2010 Sep-Oct;38(5):1876-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Craniopharyngiomas are histologically benign epithelial tumours arising from squamous epithelial remnants of Rathke's pouch, which have a tendency to invade surrounding structures and recur after apparently complete resection.
  • They represent the most frequent non-glial tumour in children, accounting for approximately 5% of paediatric brain neoplasms.
  • [MeSH-major] Craniopharyngioma / secondary. Neoplasm Recurrence, Local / pathology. Pituitary Neoplasms / pathology

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21309505.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Kusafuka K, Ueno T, Kurihara K, Murata T, Yurikusa T, Henmi H, Akane M, Ota Y, Kameya T: Cystadenoma of the palate: immunohistochemistry of mucins. Pathol Int; 2008 Aug;58(8):524-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystadenoma is a relatively rare benign epithelial tumor of the salivary glands, and described herein is an additional case.
  • Histologically, the tumor was composed of bilayered columnar epithelium with cystic change and partial solid growth of glandular structures with clear cells.
  • The tumor cells had mild cellular atypia, but the tumor lacked papillary growth and a fibrous capsule.
  • Immunohistochemistry was positive for cytokeratins, epithelial membrane antigen, MUC1, MUC4 and MUC6, but negative for myoepithelial markers, MUC2, MUC5AC and MUC5B.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Humans. Immunohistochemistry. Male. Middle Aged

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705774.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


15. De Sousa Damião R, Fujiyama Oshima CT, Stávale JN, Gonçalves WJ: Analysis of the expression of estrogen receptor, progesterone receptor and chicken ovalbumin upstream promoter-transcription factor I in ovarian epithelial cancers and normal ovaries. Oncol Rep; 2007 Jul;18(1):25-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the expression of estrogen receptor, progesterone receptor and chicken ovalbumin upstream promoter-transcription factor I in ovarian epithelial cancers and normal ovaries.
  • In the ovary, this role is not clearly defined, with epithelial cancers being poorly responsive to hormone therapy.
  • To investigate the role of these receptors in ovarian carcinogenesis and their implications for cancer prognosis, we evaluated the immunohistochemical expression of ER, progesterone receptor (PR) and COUP-TFI in benign and malignant ovarian epithelial neoplasms and in normal ovaries.
  • A total of 113 ovarian specimens, including 40 diagnosed as malignant epithelial neoplasms (group A), 45 as benign epithelial tumors (group B), and 28 from normal ovaries (group C) were analyzed.
  • Multivariate analysis revealed a residual tumor <1 cm as the most significant clinical prognostic factor in group A (p=0.010, OR=4.14).
  • [MeSH-major] COUP Transcription Factor I / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Ovary / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549341.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / COUP Transcription Factor I; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


16. Pereira PD, Lopes CC, Matos AJ, Cortez PP, Gärtner F, Medeiros R, Lopes C: Caveolin-1 in diagnosis and prognosis of canine mammary tumours: comparison of evaluation systems. J Comp Pathol; 2010 Aug-Oct;143(2-3):87-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caveolin-1 in diagnosis and prognosis of canine mammary tumours: comparison of evaluation systems.
  • Results obtained with both scoring methods were similar, revealing absence of immunoreactivity in normal luminal epithelium and in benign neoplasms and clearly associating Cav-1 expression with malignant transformation.
  • The data suggest that Cav-1 expression is associated with highly malignant subtypes of mammary tumours (i.e. basal-like carcinoma), invasion and metastasis, thus supporting the hypothesis that it may play a major role in the epithelial-mesenchymal transition process.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma / veterinary. Caveolin 1 / metabolism. Dog Diseases / diagnosis. Mammary Glands, Animal / metabolism. Mammary Neoplasms, Animal / diagnosis
  • [MeSH-minor] Animals. Caveolae / metabolism. Dogs. Female. Immunohistochemistry. Neoplasm Invasiveness. Neoplasm Metastasis. Prognosis. Research Design. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20153868.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Caveolin 1
  •  go-up   go-down


17. Basile JR, Klene C, Lin YL: Calcifying odontogenic cyst with odontogenic keratocyst: a case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Apr;109(4):e40-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The calcifying odontogenic cyst (COC), first identified as a separate and distinct lesion by Gorlin et al. in 1962, is an uncommon benign lesion, consisting of a proliferation of odontogenic epithelium and scattered nests of ghost cells and calcifications that may form the lining of a cyst or present as a solid mass.
  • The COC occurs alone or occasionally with odontomas or other odontogenic tumors, and it is this variable histology and clinical behavior that has raised the question of whether or not it is a cyst or a true neoplasm.
  • The odontogenic keratocyst (OKC) is a locally aggressive odontogenic cyst lined by parakeratinizing epithelium that also exhibits characteristics of a neoplasm, including rapid growth, a high rate of recurrence when treated conservatively, and the presence of a gene mutation.
  • [MeSH-major] Mandibular Diseases / complications. Maxillary Neoplasms / complications. Odontogenic Cyst, Calcifying / complications. Odontogenic Cysts / complications
  • [MeSH-minor] Adult. Ameloblasts / pathology. Biopsy. Connective Tissue / pathology. Diagnosis, Differential. Epithelium / pathology. Humans. Keratins. Male

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20303045.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins
  • [Number-of-references] 20
  •  go-up   go-down


18. Nykopp TK, Rilla K, Sironen R, Tammi MI, Tammi RH, Hämäläinen K, Heikkinen AM, Komulainen M, Kosma VM, Anttila M: Expression of hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in serous ovarian carcinomas: inverse correlation between HYAL1 and hyaluronan content. BMC Cancer; 2009;9:143
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hyaluronan, a tumor promoting extracellular matrix polysaccharide, is elevated in malignant epithelial ovarian tumors, and associates with an unfavorable prognosis.
  • METHODS: Normal ovaries (n = 5) and 34 serous epithelial ovarian tumors, divided into 4 groups: malignant grades 1+2 (n = 10); malignant grade 3 (n = 10); borderline (n = 4) and benign epithelial tumors (n = 10), were analyzed for mRNA by real-time RT-PCR and compared to hyaluronidase activity, hyaluronan staining, and HAS1-3 immunoreactivity in tissue sections of the same specimens.
  • CONCLUSION: The results indicate that in serous epithelial ovarian malignancies HAS expression is not consistently elevated but HYAL1 expression is significantly reduced and correlates with the accumulation of hyaluronan. (233 words).

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2009 Mar;174(3):1027-36 [19218337.001]
  • [Cites] Matrix Biol. 2008 Oct;27(8):653-60 [18762256.001]
  • [Cites] J Biol Chem. 2001 Feb 2;276(5):3361-70 [11058590.001]
  • [Cites] J Biol Chem. 2001 Sep 14;276(37):35111-22 [11451952.001]
  • [Cites] Matrix Biol. 2001 Dec;20(8):499-508 [11731267.001]
  • [Cites] Matrix Biol. 2001 Dec;20(8):509-14 [11731268.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):4593-6 [11717318.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38013-20 [12145277.001]
  • [Cites] Int J Cancer. 2002 Nov 20;102(3):212-9 [12397638.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6410-3 [12438225.001]
  • [Cites] Int J Cancer. 2003 Nov 10;107(3):359-64 [14506734.001]
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5318-24 [14614016.001]
  • [Cites] Int J Cancer. 2004 Mar 20;109(2):247-52 [14750176.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7832-7 [8755562.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1228-32 [9102203.001]
  • [Cites] J Biol Chem. 1997 May 30;272(22):13997-4000 [9206724.001]
  • [Cites] Int J Cancer. 1997 Nov 4;73(3):327-31 [9359477.001]
  • [Cites] Lab Invest. 1998 Aug;78(8):987-1003 [9714186.001]
  • [Cites] Int J Cancer. 2005 Jan 10;113(2):207-12 [15386412.001]
  • [Cites] Carcinogenesis. 2005 Jan;26(1):65-72 [15358636.001]
  • [Cites] Lab Invest. 2005 Jan;85(1):154-9 [15543203.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2243-50 [15781637.001]
  • [Cites] Int J Oncol. 2005 Jun;26(6):1681-9 [15870886.001]
  • [Cites] Pathol Biol (Paris). 2005 Sep;53(7):372-82 [16085113.001]
  • [Cites] Arkh Patol. 2005;Suppl:1-64 [16108150.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7782-9 [16140946.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):483-91 [18199543.001]
  • [Cites] Glycobiology. 2008 Apr;18(4):280-9 [18234732.001]
  • [Cites] Cancer Res. 2000 Jan 1;60(1):150-5 [10646867.001]
  • (PMID = 19435493.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 9004-61-9 / Hyaluronic Acid; EC 2.4.1.17 / Glucuronosyltransferase; EC 2.4.1.212 / hyaluronan synthase; EC 3.2.1.35 / Hyaluronoglucosaminidase
  • [Other-IDs] NLM/ PMC2689240
  •  go-up   go-down


19. Bologna-Molina R, Mosqueda-Taylor A, de Almeida-Oslei P, Toral-Rizo V, Martínez-Mata G: Peripheral desmoplastic ameloblastoma: histopathological and immunohistochemical profile of a case. Med Oral Patol Oral Cir Bucal; 2010 Nov;15(6):e846-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This article reports a new case of this unusual neoplasm in a 66 year-old woman in which the main complaint was an asymptomatic swelling located in the right body of mandible.
  • Histopathological findings were similar to the two previously reported cases of this tumor.
  • Positive immunohistochemical stain for laminin V and type IV collagen suggests an inductive effect of the epithelium over the stroma while the low index of p53 protein and Ki-67 expression in epithelium and stromal cells, as well as CD138 uniform positive-stain in epithelial cells, support the benign biological behavior of this lesion.
  • Including this new case, currently there are only three reports of this rare neoplasm.
  • Reports of new cases of peripheral desmoplastic ameloblastoma are necessary for a better understanding of the origin and behavior of this particular subtype of ameloblastoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20526273.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


20. Sisci D, Morelli C, Garofalo C, Romeo F, Morabito L, Casaburi F, Middea E, Cascio S, Brunelli E, Andò S, Surmacz E: Expression of nuclear insulin receptor substrate 1 in breast cancer. J Clin Pathol; 2007 Jun;60(6):633-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: To assess whether nuclear IRS-1 is present in breast cancer and non-cancer mammary epithelium, and whether it correlates with other markers, especially ERalpha.
  • RESULTS: Median nuclear IRS-1 expression was found to be low in normal mammary epithelial cells (1.6%) and high in benign tumours (20.5%), ductal grade 2 carcinoma (11.0%) and lobular carcinoma (approximately 30%).
  • Median ERalpha expression in normal epithelium, benign tumours, ductal cancer grade 2 and 3, and lobular cancer grade 2 and 3 were 10.5, 20.5, 65.0, 0.0, 80 and 15%, respectively.
  • Nuclear IRS-1 and ERalpha positively correlated in ductal cancer (p<0.001) and benign tumours (p<0.01), but were not associated in lobular cancer and normal mammary epithelium.
  • In ductal carcinoma, both nuclear IRS-1 and ERalpha negatively correlated with tumour grade, size, mitotic index and lymph node involvement.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. Cell Nucleus / metabolism. Phosphoproteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Cytoplasm / metabolism. Estrogen Receptor alpha / metabolism. Female. Humans. Immunoenzyme Techniques. Insulin Receptor Substrate Proteins. Mammary Glands, Human / metabolism. Microscopy, Confocal. Middle Aged. Neoplasm Invasiveness. Neoplasm Proteins / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 Mar 30;276(13):9817-24 [11139588.001]
  • [Cites] J Cell Physiol. 2006 Jan;206(1):35-46 [15965906.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6747-54 [11559546.001]
  • [Cites] Endocr Relat Cancer. 2001 Sep;8(3):197-209 [11566611.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Nov 2;288(3):685-9 [11676497.001]
  • [Cites] J Biol Chem. 2002 May 10;277(19):17231-8 [11877394.001]
  • [Cites] J Biol Chem. 2002 Aug 30;277(35):32078-85 [12063262.001]
  • [Cites] J Cell Physiol. 2003 Feb;194(2):108-16 [12494449.001]
  • [Cites] Oncogene. 2003 Jun 26;22(26):4007-16 [12821935.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6589-97 [14528284.001]
  • [Cites] Int J Cancer. 2003 Dec 20;107(6):873-7 [14601044.001]
  • [Cites] Metabolism. 2003 Dec;52(12):1606-11 [14669164.001]
  • [Cites] Horm Metab Res. 2003 Nov-Dec;35(11-12):794-801 [14710360.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9272-6 [15197263.001]
  • [Cites] Oncogene. 2004 Sep 30;23(45):7517-26 [15318176.001]
  • [Cites] J Clin Invest. 1973 Jan;52(1):73-7 [4345203.001]
  • [Cites] Monogr Pathol. 1984;(25):149-74 [6377047.001]
  • [Cites] Bull Cancer. 1989;76(3):311-9 [2544239.001]
  • [Cites] Clin Chem. 1993 Jun;39(6):1345-6 [7684958.001]
  • [Cites] Cancer Res. 1993 Aug 15;53(16):3736-40 [8339284.001]
  • [Cites] Eur J Cancer. 1994;30A(3):307-11 [8204350.001]
  • [Cites] Cancer. 1994 Jul 1;74(1 Suppl):381-400 [8004612.001]
  • [Cites] Trends Biochem Sci. 1994 Jul;19(7):289-93 [8048169.001]
  • [Cites] J Cell Biochem. 2000 Jan;76(4):605-14 [10653980.001]
  • [Cites] J Biol Chem. 2000 Apr 28;275(17):12565-71 [10777546.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Jan;5(1):95-105 [10791772.001]
  • [Cites] Prev Vet Med. 2000 May 30;45(1-2):23-41 [10802332.001]
  • [Cites] Heart. 2000 Jul;84(1):71-8 [10862595.001]
  • [Cites] Int J Cancer. 2000 Nov 20;89(6):506-13 [11102895.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5574-81 [11114737.001]
  • [Cites] Breast Cancer Res Treat. 1994;32(1):85-95 [7529598.001]
  • [Cites] Science. 1995 Dec 1;270(5241):1491-4 [7491495.001]
  • [Cites] Endocrinology. 1996 May;137(5):1735-44 [8612509.001]
  • [Cites] EMBO J. 1996 Mar 15;15(6):1292-300 [8635462.001]
  • [Cites] Ann N Y Acad Sci. 1996 Apr 30;784:189-201 [8651569.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1996;36:615-58 [8725404.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2606-10 [9205064.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3079-83 [9242428.001]
  • [Cites] Diabetologia. 1997 Jul;40 Suppl 2:S2-17 [9248696.001]
  • [Cites] Int J Cancer. 1997 Sep 4;72(5):828-34 [9311601.001]
  • [Cites] J Pathol. 1997 Dec;183(4):412-7 [9496257.001]
  • [Cites] Breast Cancer Res Treat. 1998 Feb;47(3):295-302 [9516083.001]
  • [Cites] Recent Prog Horm Res. 1998;53:119-38 [9769706.001]
  • [Cites] Clin Cancer Res. 1995 Nov;1(11):1429-36 [9815941.001]
  • [Cites] Clin Cancer Res. 1996 Dec;2(12):2037-42 [9816164.001]
  • [Cites] Clin Cancer Res. 1997 Jan;3(1):103-9 [9815544.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Dec 18;253(2):315-9 [9878535.001]
  • [Cites] Recent Results Cancer Res. 1998;152:63-70 [9928547.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):299-304 [10188734.001]
  • [Cites] Mol Endocrinol. 1999 May;13(5):787-96 [10319328.001]
  • [Cites] J Exp Clin Cancer Res. 2004 Sep;23(3):385-94 [15595626.001]
  • [Cites] J Clin Pathol. 2005 Jun;58(6):645-9 [15917419.001]
  • [Cites] J Biol Chem. 2005 Aug 19;280(33):29912-20 [15967802.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2545-54 [11489838.001]
  • (PMID = 16882697.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Estrogen Receptor alpha; 0 / IRS1 protein, human; 0 / Insulin Receptor Substrate Proteins; 0 / Neoplasm Proteins; 0 / Phosphoproteins
  • [Other-IDs] NLM/ PMC1955087
  •  go-up   go-down


21. Cao D, Polyak K, Halushka MK, Nassar H, Kouprina N, Iacobuzio-Donahue C, Wu X, Sukumar S, Hicks J, De Marzo A, Argani P: Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4 and overexpression of matrix metalloproteinase 9. Breast Cancer Res; 2008;10(5):R91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By comparing the gene expression profile of LCIS to that of benign breast epithelium and stroma, we identified several genes up and down regulated in LCIS.
  • RESULTS: We identified down regulation of claudin 4 and overexpression of matrix metalloproteinase 9 in LCIS relative to normal breast epithelium and stroma.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1999 Oct;189(2):161-8 [10547569.001]
  • [Cites] Histopathology. 2005 May;46(5):551-60 [15842637.001]
  • [Cites] Breast Cancer Res Treat. 2000 Aug;62(3):197-210 [11072784.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):17-32 [15261139.001]
  • [Cites] JAMA. 1967 Jul 10;201(2):82-6 [6072345.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):741-51 [15696125.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9603-6 [16266975.001]
  • [Cites] Cancer. 2006 May 15;106(10):2104-12 [16604564.001]
  • [Cites] Adv Anat Pathol. 2006 Jul;13(4):157-65 [16858149.001]
  • [Cites] BMC Cancer. 2006;6:186 [16836752.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):427-37 [17325485.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Sep;15(3):260-6 [17721269.001]
  • [Cites] Virchows Arch. 2007 Sep;451(3):669-80 [17609977.001]
  • [Cites] Am J Surg Pathol. 2008 Apr;32(4):513-23 [18223478.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4606-13 [18559505.001]
  • [Cites] Cancer Cell. 2008 Jul 8;14(1):5-7 [18598938.001]
  • [Cites] Hum Pathol. 2001 Mar;32(3):292-6 [11274638.001]
  • [Cites] Br J Cancer. 2001 Jun 1;84(11):1488-96 [11384099.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4320-4 [11389052.001]
  • [Cites] Int J Surg Pathol. 2001 Apr;9(2):127-31 [11484500.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3862-8 [11751476.001]
  • [Cites] Lancet. 2003 Jan 11;361(9352):125-9 [12531579.001]
  • [Cites] Int J Cancer. 2003 Aug 20;106(2):208-15 [12800196.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):653-61 [12875984.001]
  • [Cites] Int J Cancer. 2003 Dec 20;107(6):970-5 [14601057.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):226-30 [14983936.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1627-33 [15111309.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2562-72 [15197797.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] Cancer. 1974 Sep;34(3):554-63 [4853024.001]
  • [Cites] Cancer. 1996 Oct 1;78(7):1403-16 [8839545.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 May;6(5):297-301 [9149887.001]
  • [Cites] Br J Cancer. 1997;76(9):1131-3 [9365159.001]
  • [Cites] J Surg Oncol. 1998 Jan;67(1):41-6 [9457256.001]
  • [Cites] J Pathol. 1997 Dec;183(4):404-11 [9496256.001]
  • [Cites] Annu Rev Physiol. 1998;60:121-42 [9558457.001]
  • [Cites] Cancer Res. 1998 Jul 1;58(13):2876-80 [9661905.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4721-7 [9788628.001]
  • [Cites] Histopathology. 1999 Sep;35(3):195-200 [10469210.001]
  • [Cites] Semin Diagn Pathol. 1999 Aug;16(3):209-23 [10490198.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1531-6 [15619213.001]
  • [Cites] Oncol Rep. 2005 Feb;13(2):193-9 [15643498.001]
  • [Cites] Breast Cancer Res. 2005;7(2):R296-305 [15743508.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1135-49 [10694567.001]
  • (PMID = 18954444.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA088843; United States / NCI NIH HHS / CA / P50 CA88843
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CLDN4 protein, human; 0 / Claudin-4; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ PMC2614499
  •  go-up   go-down


22. Ryan CJ, Haqq CM, Simko J, Nonaka DF, Chan JM, Weinberg V, Small EJ, Goldfine ID: Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer. Urol Oncol; 2007 Mar-Apr;25(2):134-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite this targeting, there are conflicting data on the presence of this receptor in human tumor samples, largely because of differences in technique.
  • RESULTS: IGF-1 receptor was expressed in normal prostate epithelium in 6 of 6 patients without cancer and in morphologically normal epithelium adjacent to tumor cells in 21 of 22 patients with cancer studied.
  • IGF-1 receptor was present in the prostate tumor epithelium of 28 of 28 primary tumors, 3 of 5 locally recurrent androgen-independent tumors, and in 4 of 5 metastatic lymph nodes.
  • Stromal staining patterns were positive in 2 of 28 specimens near benign epithelium compared to 19 of 30 specimens of stroma surrounding tumor epithelium (P < 0.0001, Fisher exact test).
  • Stroma adjacent to Gleason grade >or=7 tumors showed higher intensity staining than that adjacent to lower grade tumors (P < 0.001).
  • Expression of the closely related insulin receptor did not show expression in either normal or cancer epithelium, or in adjacent stroma.
  • [MeSH-major] Neoplasm Recurrence, Local / metabolism. Neoplasms, Hormone-Dependent / metabolism. Prostatic Neoplasms / metabolism. Receptor, IGF Type 1 / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Aged. Aged, 80 and over. Biomarkers, Tumor. Epithelium / metabolism. Epithelium / pathology. Humans. Lymph Nodes. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis. Prostate / metabolism. Prostate / pathology. Receptor, Insulin / metabolism. Receptors, Androgen / metabolism. Stromal Cells / metabolism

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17349528.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA115775-01; United States / NCI NIH HHS / CA / P50 CA89520; United States / NCI NIH HHS / CA / R01 CA101042-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Androgen; EC 2.7.10.1 / Receptor, IGF Type 1; EC 2.7.10.1 / Receptor, Insulin
  •  go-up   go-down


23. Oxenius I, Vacirca F: [A rare case of fibroepithelial polyp of the proximal urethra in a young woman]. Urologia; 2008 Jul-Sep;75(3):193-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fibroepithelial polyps are benign epithelial tumours which are rare in adults.
  • We report a case of a twenty-seven-year-old woman, presenting with painless terminal gross haematuria, affected by a neoplasm located in the proximal urethra near the bladder neck.
  • Endoscopic image of the tumour and histopatological details are shown.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21086351.001).
  • [ISSN] 0391-5603
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Xu J, Zhang S, You C, Wang X, Zhou Q: Microvascular density and vascular endothelial growth factor have little correlation with prognosis of craniopharyngioma. Surg Neurol; 2006;66 Suppl 1:S30-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Craniopharyngioma is histologically a benign epithelial tumor located in the supersellar cistern that often presents aggressive growth and repeated recurrence.
  • METHODS: The cohorts consisted of 32 patients with AE and 31 patients with SP tumor.
  • CONCLUSIONS: Microvascular density and VEGF in craniopharyngioma tissue have no correlation with prognosis of the tumor, which may be explained by the minimal blood circulation in the craniopharyngioma.
  • Adamantine epithelioma showed more tendency to recur than SP.
  • [MeSH-major] Craniopharyngioma / blood supply. Craniopharyngioma / metabolism. Neoplasm Recurrence, Local / etiology. Pituitary Neoplasms / blood supply. Pituitary Neoplasms / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16904996.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


25. Yantiss RK, Woda BA, Fanger GR, Kalos M, Whalen GF, Tada H, Andersen DK, Rock KL, Dresser K: KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol; 2005 Feb;29(2):188-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas.
  • The purposes of this study were 1) to assess KOC mRNA expression in pancreatic carcinoma, 2) to determine the pattern of KOC immunoexpression among benign, borderline, and malignant pancreatic epithelial lesions, and 3) to evaluate the utility of the KOC antibody in distinguishing between these entities. mRNA was isolated from fresh pancreatic tissues (19 carcinomas, 2 normal pancreas, 1 chronic pancreatitis) and amplified using standard RT-PCR techniques.
  • Fifteen of 19 (79%) carcinomas overexpressed KOC mRNA relative to non-neoplastic tissue samples and expression increased progressively with tumor stage: the mean copy number of KOC mRNA transcripts was 1.5, 11.1, 31, and 28 for stage I, II, III, and IV carcinomas, respectively, compared with 0.9 and 1 for normal pancreatic tissue and chronic pancreatitis, respectively.
  • KOC staining was present in 37 of 38 (97%) carcinomas: the staining reaction was moderate or strong in 36 of 38 (94%) and present in >50% of the tumor cells in 35 of 38 (92%) cases.
  • Severe dysplasia of the ductal epithelium, present in 19 foci of intraductal papillary mucinous carcinoma, mucinous cystadenocarcinoma, and grade 3 pancreatic intraepithelial neoplasia (PanIN3) showed strong or moderate staining in 15 (79%) cases, whereas foci of mild and moderate dysplasia (intraductal papillary-mucinous neoplasms and mucinous cystic neoplasms with adenoma and/or moderate dysplasia, PanIN1, and PanIN2) were uniformly negative for this marker in 25 and 22 cases, respectively.
  • In the normal pancreas, weak background staining of acini was present in 12 of 50 (24%) cases but was easily distinguishable from the type of staining identified in neoplastic epithelium, and benign ducts and ductules were negative in all cases.
  • We conclude that KOC is a sensitive and specific marker for carcinomas and high-grade dysplastic lesions of the pancreatic ductal epithelium.
  • [MeSH-major] Biomarkers, Tumor / analysis. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. RNA-Binding Proteins / metabolism
  • [MeSH-minor] Animals. Humans. Immunohistochemistry. Neoplasm Proteins. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15644775.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA-Binding Proteins
  •  go-up   go-down


26. Koch P, Petri M, Paradowska A, Stenzinger A, Sturm K, Steger K, Wimmer M: PTPIP51 mRNA and protein expression in tissue microarrays and promoter methylation of benign prostate hyperplasia and prostate carcinoma. Prostate; 2009 Dec 1;69(16):1751-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PTPIP51 mRNA and protein expression in tissue microarrays and promoter methylation of benign prostate hyperplasia and prostate carcinoma.
  • In this study the expression of PTPIP51 and its in vitro interaction partners was investigated in human benign prostate hyperplasia (BPH) and in prostate carcinoma (PCa).
  • RESULTS: PTPIP51 mRNA and protein expression was detected in prostatic epithelia of BPH and in tumor cells of PCa, respectively, and within smooth muscle cells of the stromal compartment.
  • [MeSH-minor] Aged. CpG Islands / genetics. Endothelial Cells / metabolism. Epithelium / metabolism. Humans. Immune System / metabolism. Immune System / pathology. Male. Microarray Analysis. Middle Aged. Muscle, Smooth, Vascular / metabolism. Muscle, Smooth, Vascular / pathology. Myocytes, Smooth Muscle / metabolism. Neoplasm Invasiveness. Nerve Fibers / metabolism. Prostate / blood supply. Prostate / innervation. Prostate / metabolism. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley-Liss, Inc.
  • (PMID = 19691131.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mitochondrial Proteins; 0 / RNA, Messenger; EC 3.1.3.48 / FAM82A2 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down


27. Wiel J, Luis W, Kempf HG: [The interesting case -- case no. 70]. Laryngorhinootologie; 2005 Mar;84(3):196-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We will report two cases of newborn girls, who could not be breast fed because of a benign tumour in their oral cavity.
  • Tumours were fleshy, firm, dark-brown with a broad-based attachment to the alveolar ridge.
  • The size of neoplasm was in one case 3 x 2 cm, in the other one 2 x 1.5 cm.
  • Histological findings showed large tumour cells with abundant granular eosinophilic cytoplasm and a prominent vascularity.
  • All these findings are characteristic of congenital granular cell tumour and its synonym congenital epulis.
  • It differs from adult granular cell tumours by its prominent vascularity, the presence of scattered remnants of odontogenic epithelium, and the strong phosphatase activity.
  • The exact nature of this condition is still not clear, and there is little support for its originating from odontogenic epithelial cells.
  • [MeSH-major] Gingival Neoplasms / congenital. Granular Cell Tumor / congenital. Mouth Neoplasms / congenital

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15770569.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


28. Guttery DS, Hancox RA, Mulligan KT, Hughes S, Lambe SM, Pringle JH, Walker RA, Jones JL, Shaw JA: Association of invasion-promoting tenascin-C additional domains with breast cancers in young women. Breast Cancer Res; 2010;12(4):R57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Tenascin-C (TNC) is a large extracellular matrix glycoprotein that shows prominent stromal expression in many solid tumours.
  • The profile of isoforms expressed differs between cancers and normal breast, with the two additional domains AD1 and AD2 considered to be tumour associated.
  • The aim of the present study was to investigate expression of AD1 and AD2 in normal, benign and malignant breast tissue to determine their relationship with tumour characteristics and to perform in vitro functional assays to investigate the role of AD1 in tumour cell invasion and growth.
  • METHODS: Expression of AD1 and AD2 was related to hypoxanthine phosphoribosyltransferase 1 as a housekeeping gene in breast tissue using quantitative RT-PCR, and the results were related to clinicopathological features of the tumours.
  • Statistical analysis was performed using a nonparametric Mann-Whitney test for comparison of clinicopathological features with levels of TNC expression and using Jonckheere-Terpstra trend analysis for association of expression with tumour grade.
  • AD1 mRNA was localised by in situ hybridisation to tumour epithelial cells, and more predominantly to myoepithelium around associated normal breast ducts.
  • Although not tumour specific, AD1 and AD2 expression was significantly more frequent in carcinomas in younger women (age ≤40 years; P < 0.001) and AD1 expression was also associated with oestrogen receptor-negative and grade 3 tumours (P < 0.05).
  • AD1 was found to be incorporated into a tumour-specific isoform, not detected in normal tissues.
  • Overexpression of the TNC-14/AD1/16 isoform significantly enhanced tumour cell invasion (P < 0.01) and growth (P < 0.01) over base levels.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2000 Jan;105(1):21-34 [10619858.001]
  • [Cites] Br J Cancer. 1996 Dec;74(11):1796-800 [8956795.001]
  • [Cites] Matrix Biol. 2000 Dec;19(7):581-96 [11102748.001]
  • [Cites] Lancet. 2001 Jun 23;357(9273):1992-4 [11438127.001]
  • [Cites] Cell Struct Funct. 2001 Jun;26(3):179-87 [11565810.001]
  • [Cites] Int J Cancer. 2002 Mar 10;98(2):205-9 [11857409.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1152-6 [11948127.001]
  • [Cites] Semin Cancer Biol. 2002 Apr;12(2):97-104 [12027581.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3289-97 [12036947.001]
  • [Cites] Eur J Cancer. 2002 Dec;38(18):2362-70 [12460779.001]
  • [Cites] Am J Pathol. 2003 Jun;162(6):1857-67 [12759243.001]
  • [Cites] Int J Cancer. 2003 Aug 10;106(1):8-16 [12794751.001]
  • [Cites] J Pathol. 2003 Dec;201(4):562-72 [14648659.001]
  • [Cites] Science. 2004 Feb 6;303(5659):775-7 [14764858.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7377-85 [15492259.001]
  • [Cites] N Engl J Med. 1986 Aug 28;315(9):559-63 [3736639.001]
  • [Cites] J Cell Biol. 1991 Nov;115(4):1127-36 [1720121.001]
  • [Cites] J Cell Physiol. 1992 Mar;150(3):534-44 [1537883.001]
  • [Cites] Lancet. 1992 Jun 13;339(8807):1483 [1351156.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5190-7 [1382837.001]
  • [Cites] Int J Cancer. 1992 Nov 11;52(5):688-92 [1385335.001]
  • [Cites] Nucleic Acids Res. 1993 Jan 11;21(1):163-8 [7680113.001]
  • [Cites] Lancet. 1993 Apr 24;341(8852):1039-43 [8096955.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10154-8 [7694284.001]
  • [Cites] Development. 1994 Mar;120(3):637-47 [7512896.001]
  • [Cites] J Cell Biol. 1994 Jul;126(2):539-48 [7518469.001]
  • [Cites] Mol Biol Cell. 1994 Apr;5(4):439-53 [7519905.001]
  • [Cites] FEBS Lett. 1994 Sep 26;352(2):216-8 [7523186.001]
  • [Cites] J Biol Chem. 1995 Apr 14;270(15):8650-4 [7536739.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):97-103 [8630946.001]
  • [Cites] FEBS Lett. 1996 Jul 8;389(3):304-8 [8766721.001]
  • [Cites] Mol Biol Cell. 1996 Jun;7(6):883-92 [8816995.001]
  • [Cites] Br J Cancer. 1996 Oct;74(7):999-1004 [8855965.001]
  • [Cites] Int J Cancer. 1997 Jul 17;72(2):236-40 [9219826.001]
  • [Cites] Differentiation. 1997 Nov;62(2):71-82 [9404002.001]
  • [Cites] J Cell Sci. 1998 Apr;111 ( Pt 8):1095-104 [9512505.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1998 Jun;39(7):1135-42 [9620072.001]
  • [Cites] Br J Cancer. 1998 Dec;78(11):1507-13 [9836485.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1345-52 [10329587.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):477-83 [10404058.001]
  • [Cites] Cell. 1999 Jul 23;98(2):137-46 [10428026.001]
  • [Cites] Mol Biol Cell. 1999 Sep;10(9):2933-43 [10473637.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4003-11 [15930334.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5175-80 [16033833.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3200-8 [16707621.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):515-27 [17157791.001]
  • [Cites] Histopathology. 2007 Mar;50(4):434-8 [17448018.001]
  • [Cites] Mol Biol Cell. 2007 Nov;18(11):4615-24 [17855508.001]
  • [Cites] J Biol Chem. 2007 Nov 30;282(48):34929-37 [17901052.001]
  • [Cites] Breast Cancer Res. 2007;9(6):404; author reply 405 [18279542.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1368-76 [18316557.001]
  • [Cites] Cancer Res. 2008 Sep 1;68(17):6942-52 [18757408.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5555-64 [18765548.001]
  • [Cites] Breast Cancer Res. 2009;11(2):R24 [19405959.001]
  • [Cites] J Vis Exp. 2009;(29). pii: 1475. doi: 10.3791/1475 [19620957.001]
  • [Cites] J Pathol. 1999 Dec;189(4):475-80 [10629546.001]
  • (PMID = 20678196.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / Tenascin
  • [Other-IDs] NLM/ PMC2949648
  •  go-up   go-down


29. Mandinova A, Kolev V, Neel V, Hu B, Stonely W, Lieb J, Wu X, Colli C, Han R, Pazin MJ, Ostano P, Dummer R, Brissette JL, Dotto GP: A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans. J Clin Invest; 2009 Oct;119(10):3127-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans.
  • Seborrheic keratoses (SKs) are common, benign epithelial tumors of the skin that do not, or very rarely, progress into malignancy, for reasons that are not understood.
  • We investigated this by gene expression profiling of human SKs and cutaneous squamous cell carcinomas (SCCs) and found that several genes previously connected with keratinocyte tumor development were similarly modulated in SKs and SCCs, whereas the expression of others differed by only a few fold.
  • Knockdown of FOXN1 expression in primary human keratinocytes cooperated with oncogenic RAS in the induction of SCC-like tumors, whereas increased FOXN1 expression triggered the SCC cells to shift to a benign SK-like tumor phenotype, which included increased FGFR3 expression.
  • Thus,we have uncovered a positive regulatory loop between FGFR3 and FOXN1 that underlies a benign versus malignant skin tumor phenotype.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2006 Apr 15;20(8):1028-42 [16618808.001]
  • [Cites] J Clin Invest. 2006 Aug;116(8):2201-2207 [16841094.001]
  • [Cites] J Invest Dermatol. 2006 Nov;126(11):2404-7 [16778799.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3465-71 [16849642.001]
  • [Cites] Oral Oncol. 2007 Jan;43(1):60-6 [16807070.001]
  • [Cites] EMBO J. 2007 Mar 7;26(5):1268-78 [17304214.001]
  • [Cites] Genes Dev. 2007 Mar 1;21(5):562-77 [17344417.001]
  • [Cites] Mol Cell Biol. 2007 May;27(10):3732-42 [17353266.001]
  • [Cites] J Invest Dermatol. 2007 Aug;127(8):1883-5 [17392824.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13450-4 [17673550.001]
  • [Cites] Cell. 2007 Sep 7;130(5):932-42 [17803914.001]
  • [Cites] Differentiation. 2007 Oct;75(8):694-701 [17459087.001]
  • [Cites] World J Urol. 2007 Dec;25(6):581-93 [17912529.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):342-6 [18223206.001]
  • [Cites] Neoplasia. 2008 Jan;10(1):1-7 [18231634.001]
  • [Cites] Curr Urol Rep. 2008 Jan;9(1):55-61 [18366975.001]
  • [Cites] EMBO J. 2008 Apr 23;27(8):1243-54 [18388864.001]
  • [Cites] Nat Cell Biol. 2008 Aug;10(8):902-11 [18604200.001]
  • [Cites] Curr Opin Oncol. 2006 May;18(3):228-33 [16552233.001]
  • [Cites] Adv Dermatol. 1999;14:307-57 [10643503.001]
  • [Cites] J Bone Miner Res. 2000 Jan;15(1):155-65 [10646125.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):690-8 [10793105.001]
  • [Cites] N Engl J Med. 2001 Mar 29;344(13):975-83 [11274625.001]
  • [Cites] J Invest Dermatol. 2001 Apr;116(4):506-10 [11286615.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2453-64 [11402340.001]
  • [Cites] J Korean Med Sci. 2001 Oct;16(5):619-22 [11641533.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):494-501 [11839669.001]
  • [Cites] J Invest Dermatol. 2002 Feb;118(2):303-9 [11841548.001]
  • [Cites] Cell Signal. 2002 Jul;14(7):585-93 [11955951.001]
  • [Cites] Curr Opin Hematol. 2002 Jul;9(4):288-93 [12042702.001]
  • [Cites] Nat Med. 2002 Oct;8(10):1105-14 [12357246.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):444-51 [12778134.001]
  • [Cites] Dev Cell. 2003 Jun;4(6):865-77 [12791271.001]
  • [Cites] Blood. 2003 Jul 15;102(2):772-3 [12835230.001]
  • [Cites] CA Cancer J Clin. 2003 Sep-Oct;53(5):292-302 [14570228.001]
  • [Cites] Nat Immunol. 2003 Nov;4(11):1128-35 [14528302.001]
  • [Cites] Am Fam Physician. 2003 Nov 15;68(10):1963-8 [14655805.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4555-62 [15231666.001]
  • [Cites] J Cell Sci. 2004 Aug 15;117(Pt 18):4157-68 [15316080.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6035-40 [15342384.001]
  • [Cites] Cancer Res. 1981 May;41(5):1657-63 [7214336.001]
  • [Cites] Cancer Res. 1985 Mar;45(3):1187-97 [2578876.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4477-80 [8402617.001]
  • [Cites] Mol Carcinog. 1994 Sep;11(1):19-28 [7916986.001]
  • [Cites] Nature. 1994 Nov 3;372(6501):103-7 [7969402.001]
  • [Cites] Genomics. 1995 Aug 10;28(3):549-59 [7490093.001]
  • [Cites] J Biol Chem. 1996 Jun 21;271(25):15292-7 [8663044.001]
  • [Cites] Genes Dev. 1996 Sep 1;10(17):2212-21 [8804315.001]
  • [Cites] Science. 1997 Jan 17;275(5298):400-2 [8994040.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3842-7 [9108066.001]
  • [Cites] Immunogenetics. 1997;46(6):509-15 [9321431.001]
  • [Cites] Trends Biochem Sci. 1998 Feb;23(2):59-62 [9538690.001]
  • [Cites] J Investig Dermatol Symp Proc. 1996 Apr;1(2):136-42 [9627707.001]
  • [Cites] Med Clin North Am. 1998 Nov;82(6):1285-307, v-vi [9889749.001]
  • [Cites] Genes Dev. 1999 Mar 1;13(5):607-19 [10072388.001]
  • [Cites] Dev Biol. 1999 Apr 15;208(2):362-74 [10191051.001]
  • [Cites] Nature. 1999 Apr 8;398(6727):473-4 [10206641.001]
  • [Cites] Hum Mol Genet. 2005 May 1;14(9):1153-60 [15772091.001]
  • [Cites] J Invest Dermatol. 2005 May;124(5):867-76 [15854024.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):107-37 [15863029.001]
  • [Cites] Dev Cell. 2005 May;8(5):665-76 [15866158.001]
  • [ErratumIn] J Clin Invest. 2010 Feb;120(2):6455. Pazin, Mike [corrected to Pazin, Michael J]
  • (PMID = 19729838.001).
  • [ISSN] 1558-8238
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / AR39190; United States / NCI NIH HHS / CA / CA16038; United States / NIAMS NIH HHS / AR / R01 AR045284; United States / NIAMS NIH HHS / AR / AR054856; United States / NCI NIH HHS / CA / R01 CA073796; United States / Intramural NIH HHS / / ZIA AG000378-03; United States / NIAMS NIH HHS / AR / AR045284-11A1; United States / NIAMS NIH HHS / AR / R01 AR045284-11A1; United States / NIAMS NIH HHS / AR / R01 AR039190; United States / NIAMS NIH HHS / AR / R01 AR055218-02; United States / NCI NIH HHS / CA / P01 CA016038; United States / NCI NIH HHS / CA / CA73796; United States / NIAMS NIH HHS / AR / AR055218-02; United States / NIAMS NIH HHS / AR / AR045284; United States / NIAMS NIH HHS / AR / R01 AR055218; United States / NIAMS NIH HHS / AR / R01 AR054856
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Forkhead Transcription Factors; 0 / Whn protein; EC 2.7.10.1 / FGFR3 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 3
  •  go-up   go-down


30. Diallo M, Cribier B, Scrivener Y: [Warty dyskeratoma: infundibular histogenesis. Anatomoclinical study of 43 cases]. Ann Dermatol Venereol; 2007 Aug-Sep;134(8-9):633-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The exact origin and classification of warty dyskeratoma in epithelial tumours are still debated.
  • The purpose of this study was to examine the relationship between this tumour and the pilosebaceous follicles.
  • DISCUSSION: Based on the histological and immunohistochemical findings, we proposed the hypothesis of benign epithelial tumour of follicular type, beginning in the pilar infundibulum.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma / pathology. Child. Darier Disease / pathology. Epithelium / pathology. Hair Follicle / pathology. Histiocytes / pathology. Humans. Keratin-1 / analysis. Keratin-10 / analysis. Keratin-17 / analysis. Keratin-19 / analysis. Keratin-5 / analysis. Keratoacanthoma / pathology. Lymphocytes / pathology. Middle Aged. Retrospective Studies. Sebaceous Glands / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Warts.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17925685.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de venereologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Keratin-1; 0 / Keratin-17; 0 / Keratin-19; 0 / Keratin-5; 147785-83-9 / Keratin-10
  •  go-up   go-down


31. Li C, Rock KL, Woda BA, Jiang Z, Fraire AE, Dresser K: IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. Mod Pathol; 2007 Feb;20(2):242-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Forty-four samples of adenocarcinoma in situ from 40 patients and 23 control cases of benign uterine cervix were included in this study.
  • In addition to benign endocervical epithelium, 19 of these 23 control cases also showed focal tubal metaplasia.
  • Fourteen of 19 (74%) tubal metaplasia cases showed p16(INK4a) immunoreactivity in >50% of the tubal metaplastic epithelium with staining intensity ranging from weak to strong.
  • Our findings demonstrate significant expression of insulin-like growth factor-II mRNA-binding protein 3 and p16(INK4a) in adenocarcinoma in situ as compared to benign endocervical glands, suggesting that expression of these biomarkers may be helpful in the distinction of adenocarcinoma in situ from benign endocervical glands, particularly in difficult borderline cases.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Carcinoma in Situ / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Neoplasm Proteins / metabolism. RNA-Binding Proteins / metabolism. Uterine Cervical Neoplasms / metabolism


32. Giordano G, D'Adda T, Gnetti L, Merisio C, Raboni S: Transitional cell carcinoma of the endometrium associated with benign ovarian brenner tumor: a case report with immunohistochemistry molecular analysis and a review of the literature. Int J Gynecol Pathol; 2007 Jul;26(3):298-304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell carcinoma of the endometrium associated with benign ovarian brenner tumor: a case report with immunohistochemistry molecular analysis and a review of the literature.
  • Transitional cell carcinoma of the endometrium (TCCE) is a subtype of endometrial carcinoma, characterized by a prominent papillary pattern, resembling the papillary carcinoma of the urothelium.
  • This neoplasm is very rare, with only 13 cases reported in the international literature.
  • In this paper, a new case of TCCE associated with benign ovarian Brenner tumor is described.
  • Moreover, immunohistochemical and molecular studies are carried out in the effort to establish the phenotype and etiology of this rare neoplasm.
  • The molecular study, by polymerase chain reaction (PCR) failing to reveal the presence of HPV DNA, demonstrates that neither the TCCE nor the ovarian Brenner tumor is caused by an HPV infection.
  • The association of TCCE with benign ovarian Brenner tumor could be a coincidental event.
  • Conversely, this finding could be the manifestation of a multicentric metaplastic process (neometaplasia), involving both the coelomic epithelium of the ovary and the Mullerian epithelium of the uterus, or the evidence of "field effect" that manifests differently at different anatomical sites.
  • In our view, other cases of TCCE associated with ovarian Brenner tumor should be reported to confirm the last 2 hypotheses.
  • [MeSH-major] Brenner Tumor / pathology. Carcinoma, Transitional Cell / pathology. Endometrial Neoplasms / pathology
  • [MeSH-minor] DNA, Neoplasm / chemistry. DNA, Neoplasm / genetics. Female. Humans. Immunohistochemistry. Middle Aged. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17581415.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


33. Rego MF, Navarrete MA, Facina G, Falzoni R, Silva R, Baracat EC, Nazario AC: Analysis of human mammary fibroadenoma by Ki-67 index in the follicular and luteal phases of menstrual cycle. Cell Prolif; 2009 Apr;42(2):241-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Fibroadenoma is the most common benign mammary condition among women aged 35 or younger.
  • Expression of Ki-67 antigen has been used to compare proliferative activity of mammary fibroadenoma epithelium in the follicular and luteal phases of the menstrual cycle.
  • MATERIALS AND METHODS: Ninety eumenorrheic women were selected for tumour excision; they were assigned to either of the two groups, according to their phase of menstrual cycle.
  • At the end of the study, 75 patients with 87 masses were evaluated by epithelial cell Ki-67 expression, blind (no information given concerning group to which any lesion belonged).
  • Median tumour size was 2.0 cm and no relationship between proliferative activity and nodule diameter was observed.
  • Average values for expression of Ki-67 (per 1000 epithelial cells) in follicular and luteal phases were 27.88 and 37.88, respectively (P = 0.116).
  • CONCLUSION: Our findings revealed that proliferative activities in the mammary fibroadenoma epithelium did not present a statistically significant difference in the follicular and luteal phases.
  • The present study contributes to clarifying that fibroadenoma is a neoplasm and does not undergo any change in the proliferative activity during the menstrual cycle.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19317807.001).
  • [ISSN] 1365-2184
  • [Journal-full-title] Cell proliferation
  • [ISO-abbreviation] Cell Prolif.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


34. Huang W, Zhang Y, Varambally S, Chinnaiyan AM, Banerjee M, Merajver SD, Kleer CG: Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1. Am J Pathol; 2008 Apr;172(4):893-904
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1.
  • The cysteine-rich protein CCN6 [or Wnt-1-induced signaling protein 3 (WISP3)] exerts tumor-suppressive effects in aggressive inflammatory breast cancer.
  • In vitro, RNA interference knockdown of CCN6 in two benign human mammary epithelial cell lines (HME and MCF10A) decreased expression of E-cadherin protein and mRNA and reduced activity of the E-cadherin promoter; this reduction was dependent on intact E-box elements.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Dec 2;18(51):7274-9 [10602481.001]
  • [Cites] Nat Rev Cancer. 2007 Jun;7(6):415-28 [17508028.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):84-9 [10655587.001]
  • [Cites] Biotechniques. 2000 Jul;29(1):78-81 [10907080.001]
  • [Cites] Mol Pathol. 2001 Apr;54(2):57-79 [11322167.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):849-59 [11891184.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1613-8 [11912130.001]
  • [Cites] Oncogene. 2002 May 9;21(20):3172-80 [12082632.001]
  • [Cites] Mol Pathol. 2002 Aug;55(4):250-61 [12147716.001]
  • [Cites] J Biol Chem. 2002 Aug 16;277(33):29399-405 [12050162.001]
  • [Cites] Semin Cancer Biol. 2002 Oct;12(5):373-9 [12191636.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Mol Pathol. 2003 Apr;56(2):127-8 [12665631.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1445-8 [12670887.001]
  • [Cites] J Biol Chem. 2003 Jun 27;278(26):24200-8 [12695522.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606-11 [14500907.001]
  • [Cites] Breast Cancer Res. 2003;5(6):R217-22 [14580257.001]
  • [Cites] Breast Cancer Res. 2004;6(1):R110-5 [14696649.001]
  • [Cites] Neoplasia. 2004 Mar-Apr;6(2):179-85 [15140407.001]
  • [Cites] Nat Cell Biol. 2004 Oct;6(10):931-40 [15448698.001]
  • [Cites] J Clin Pathol. 1993 Feb;46(2):189-90 [8459046.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14717-22 [9843955.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):869-74 [9927660.001]
  • [Cites] Exp Cell Res. 1999 Apr 10;248(1):44-57 [10094812.001]
  • [Cites] Clin Cancer Res. 1999 Sep;5(9):2511-9 [10499627.001]
  • [Cites] J Cell Biol. 2005 Jan 3;168(1):29-33 [15631989.001]
  • [Cites] J Biol Chem. 2005 Mar 4;280(9):8229-37 [15611078.001]
  • [Cites] J Biol Chem. 2005 Mar 25;280(12):11740-8 [15647282.001]
  • [Cites] Oncogene. 2005 Mar 31;24(14):2375-85 [15674322.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3179-84 [15833848.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1418-23 [15941950.001]
  • [Cites] Oncogene. 2005 Jun 23;24(27):4349-61 [15824736.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):499-508 [16107313.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):197-209 [16169465.001]
  • [Cites] Breast Cancer Res Treat. 2005 Sep;93(2):101-10 [16187229.001]
  • [Cites] Breast Cancer Res. 2005;7(6):R1080-9 [16457688.001]
  • [Cites] Nat Cell Biol. 2006 Dec;8(12):1398-406 [17072303.001]
  • [Cites] FEBS Lett. 2007 Apr 17;581(8):1617-24 [17391671.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):76-83 [10655586.001]
  • (PMID = 18321996.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K08 CA 090876; United States / NCI NIH HHS / CA / R01 CA 66712; United States / NCI NIH HHS / CA / R01 CA 107469; United States / NCI NIH HHS / CA / R01 CA107469; United States / NCI NIH HHS / CA / K08 CA090876
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCN Intercellular Signaling Proteins; 0 / Cadherins; 0 / Homeodomain Proteins; 0 / Insulin-Like Growth Factor Binding Proteins; 0 / RNA, Messenger; 0 / Repressor Proteins; 0 / Transcription Factors; 0 / WISP3 protein, human; 0 / ZEB1 protein, human; 0 / snail family transcription factors
  • [Other-IDs] NLM/ PMC2276413
  •  go-up   go-down


35. Jaggi M, Johansson SL, Baker JJ, Smith LM, Galich A, Balaji KC: Aberrant expression of E-cadherin and beta-catenin in human prostate cancer. Urol Oncol; 2005 Nov-Dec;23(6):402-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign appearing prostate epithelium was used as an internal control in each specimen.
  • Overall, the expression of E-cadherin and beta-catenin is significantly down regulated in PC compared to surrounding benign appearing prostate, which correlates with increasing Gleason grade.
  • [MeSH-minor] Cell Membrane / metabolism. Cell Membrane / pathology. Cell Nucleus / metabolism. Cell Nucleus / pathology. Humans. Male. Neoplasm Staging

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16301117.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / beta Catenin
  •  go-up   go-down


36. Jang KY, Kim KS, Hwang SH, Kwon KS, Kim KR, Park HS, Park BH, Chung MJ, Kang MJ, Lee DG, Moon WS: Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology; 2009;41(4):366-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and prognostic significance of SIRT1 in ovarian epithelial tumours.
  • Therefore, we investigated the prevalence and the prognostic impact of SIRT1 and p53 expression in ovarian epithelial tumours.
  • METHODS: Immunohistochemical expression of SIRT1 and p53 were evaluated using tissue microarray in 40 cases of benign epithelial tumours, 36 cases of borderline tumours, and 90 cases of malignant tumours.
  • RESULTS: Expression of SIRT1 was significantly increased in malignant epithelial tumours compared to benign and borderline epithelial tumours (p < 0.001).
  • Despite the frequent expression of SIRT1 in malignant ovarian epithelial tumours, serous carcinomas of high FIGO stage showed less frequent SIRT1 expression compared to that of low stage serous carcinomas (p = 0.029).
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasms, Glandular and Epithelial / metabolism. Neoplasms, Glandular and Epithelial / pathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Sirtuins / biosynthesis
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Prognosis. Sirtuin 1. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404850.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins
  •  go-up   go-down


37. Cates JM, Byrd RH, Fohn LE, Tatsas AD, Washington MK, Black CC: Epithelial-mesenchymal transition markers in pancreatic ductal adenocarcinoma. Pancreas; 2009 Jan;38(1):e1-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial-mesenchymal transition markers in pancreatic ductal adenocarcinoma.
  • OBJECTIVES: Expression of transcription factors that mediate epithelial-mesenchymal transition (EMT), such as Twist and Slug, is correlated with poor prognosis in many tumor types.
  • Selected EMT markers were studied in a series of pancreatic ductal adenocarcinomas (PDAs) and benign pancreatic tissues to determine whether expression levels correlated with diagnosis, histologic grade, or patient outcome.
  • RESULTS: Twist and Slug were identified in both the nucleus and cytoplasm of benign pancreatic ductal epithelium, chronic pancreatitis, and PDA.
  • Compared with normal ductal epithelium, nuclear levels of Twist are decreased in PDA.
  • Epithelial-mesenchymal transition marker expression was not associated with N-cadherin expression, patient outcome, or duration of survival.
  • CONCLUSIONS: Decreased expression of nuclear Twist is observed in malignant pancreatic epithelium.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 May;16(3):251-62 [18301244.001]
  • [Cites] Hum Pathol. 2007 Apr;38(4):598-606 [17258791.001]
  • [Cites] J Pathol. 2007 Apr;211(5):507-15 [17299729.001]
  • [Cites] Histopathology. 2007 Apr;50(5):648-58 [17394502.001]
  • [Cites] J Clin Pathol. 2007 May;60(5):510-4 [16822877.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jul 6;358(3):925-30 [17512904.001]
  • [Cites] Pathology. 2007 Jun;39(3):305-18 [17558857.001]
  • [Cites] J Cell Biochem. 2007 Jul 1;101(4):816-29 [17243120.001]
  • [Cites] J Surg Res. 2007 Aug;141(2):196-203 [17583745.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):303-10 [17674958.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4769-76 [17699854.001]
  • [Cites] Gene. 2000 Oct 17;257(1):1-12 [11054563.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1613-8 [11912130.001]
  • [Cites] Oncogene. 2002 May 9;21(20):3241-6 [12082640.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1881-91 [12414534.001]
  • [Cites] Int J Oncol. 2003 Apr;22(4):891-8 [12632084.001]
  • [Cites] Curr Opin Cell Biol. 2003 Dec;15(6):740-6 [14644200.001]
  • [Cites] J Histochem Cytochem. 2004 Jul;52(7):959-65 [15208362.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4125-33 [15217949.001]
  • [Cites] J Natl Cancer Inst. 1993 Feb 3;85(3):200-6 [8423624.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):188-95 [15644775.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1174-80 [15709186.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):155-65 [15790452.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1631-43 [15742334.001]
  • [Cites] Ann Surg Oncol. 2005 Jun;12(6):488-96 [15864483.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5153-62 [15958559.001]
  • [Cites] Development. 2005 Jul;132(14):3151-61 [15983400.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4524-31 [16002843.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):5991-5; discussion 5995 [16024595.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):5996-6000; discussion 6000-1 [16024596.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):197-209 [16169465.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8070-8 [16299238.001]
  • [Cites] Hum Pathol. 2006 Apr;37(4):431-8 [16564917.001]
  • [Cites] J Cell Biol. 2006 Mar 27;172(7):973-81 [16567498.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3365-9 [16585154.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1816-22 [16773075.001]
  • [Cites] J Biol Chem. 2006 Jul 28;281(30):21321-31 [16707493.001]
  • [Cites] Br J Cancer. 2007 Jan 29;96(2):314-20 [17211477.001]
  • [Cites] Int J Cancer. 2007 Apr 15;120(8):1634-40 [17236203.001]
  • (PMID = 18766116.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA095103; United States / NCI NIH HHS / CA / P50 CA095103-10; United States / NCI NIH HHS / CA / P50 CA95103
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CDH2 protein, human; 0 / Cadherins; 0 / Nuclear Proteins; 0 / TWIST1 protein, human; 0 / Transcription Factors; 0 / Twist Transcription Factor; 0 / snail family transcription factors
  • [Other-IDs] NLM/ NIHMS205920; NLM/ PMC2882851
  •  go-up   go-down


38. Depondt J, Shabana el-H, Walker F, Pibouin L, Lezot F, Berdal A: Nasal inverted papilloma expresses the muscle segment homeobox gene Msx2: possible prognostic implications. Hum Pathol; 2008 Mar;39(3):350-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nasal inverted papilloma is a rare benign tumor of epithelial origin with aggressive evolution, bone destruction, recurrence, and malignant transformation.
  • The protein expression level was directly and significantly associated with tumor recurrence.
  • [MeSH-major] Biomarkers, Tumor / analysis. DNA-Binding Proteins / biosynthesis. Homeodomain Proteins / biosynthesis. Nose Neoplasms / genetics. Nose Neoplasms / metabolism. Papilloma, Inverted / genetics. Papilloma, Inverted / metabolism
  • [MeSH-minor] Acid Phosphatase / metabolism. Adult. Aged. Female. Gene Expression. Genes, Homeobox / physiology. Humans. Immunohistochemistry. Isoenzymes / metabolism. Male. Middle Aged. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Prognosis. RANK Ligand / biosynthesis. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18187185.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Homeodomain Proteins; 0 / Isoenzymes; 0 / MSX2 protein; 0 / RANK Ligand; 0 / RNA, Messenger; 0 / TNFSF11 protein, human; EC 3.1.3.- / tartrate-resistant acid phosphatase; EC 3.1.3.2 / Acid Phosphatase
  •  go-up   go-down


39. Bignami M, Pistochini A, Meloni F, Delehaye E, Castelnuovo P: A rare case of oncocytic Schneiderian papilloma with intradural and intraorbital extension with notes of operative techniques. Rhinology; 2009 Sep;47(3):316-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epithelial cells of cylindrical cell papilloma are oncocytes, which arise from the sinonasal respiratory epithelium, hence the term Oncocytic Schneiderian papilloma.This is a rare and benign neoplasm of the nose and paranasal sinuses and it should be considered in the work-up of all unilateral nasal polypoid lesions.

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19839258.001).
  • [ISSN] 0300-0729
  • [Journal-full-title] Rhinology
  • [ISO-abbreviation] Rhinology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


40. Zhao H, Davydova L, Mandich D, Cartun RW, Ligato S: S100A4 protein and mesothelin expression in dysplasia and carcinoma of the extrahepatic bile duct. Am J Clin Pathol; 2007 Mar;127(3):374-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated the expression of S100A4 protein and mesothelin in dysplasia and carcinoma of the extrahepatic bile duct (EBD) and their potential use as adjuncts for differentiating carcinomatous and significant high-grade dysplastic epithelium from reactive or inflammatory glandular atypia of the EBD.
  • We used immunohistochemical analysis on formalin-fixed tissue sections from 10 cases of carcinoma, 6 cases of high-grade dysphasia (HGD), 4 cases of low-grade dysplasia (LGD), and 10 cases of benign or reactive or inflammatory epithelium from the EBD.
  • No case of normal or reactive epithelium was positive for S100A4 protein or mesothelin.
  • S100A4 protein alone or combined with mesothelin can be used as an adjunct in differentiating carcinomatous and significant high-grade dysplastic epithelium from LGD and reactive or inflammatory glandular atypia of the EBD.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Epithelium / chemistry. Epithelium / pathology. GPI-Linked Proteins. Humans. Immunohistochemistry. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17276942.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / S100 Proteins; 0 / mesothelin; 142662-27-9 / S100A4 protein, human
  •  go-up   go-down


41. Wang ZC, Buraimoh A, Iglehart JD, Richardson AL: Genome-wide analysis for loss of heterozygosity in primary and recurrent phyllodes tumor and fibroadenoma of breast using single nucleotide polymorphism arrays. Breast Cancer Res Treat; 2006 Jun;97(3):301-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide analysis for loss of heterozygosity in primary and recurrent phyllodes tumor and fibroadenoma of breast using single nucleotide polymorphism arrays.
  • Phyllodes tumors of the breast are biphasic stromal and epithelial tumors histologically similar to benign fibroadenomas, but with a neoplastic stromal component.
  • In contrast to fibroadenoma, phyllodes tumors can recur and be locally aggressive or be malignant.
  • This study uses SNP array analysis to present a genome-wide map of loss of heterozygosity (LOH) in a cohort of phyllodes tumors and fibroadenomas.
  • LOH is frequent and sometimes extensive in phyllodes tumors, but is rarely seen in fibroadenomas.
  • There is heterogeneity between phyllodes tumors of different patients and no one LOH marker identifies a majority of these lesions.
  • However, a subset of LOH loci occur in multiple cases of phyllodes tumors and are not found in fibroadenomas.
  • Primary phyllodes tumors and paired recurrences from the same patient share common regions of LOH.
  • Specific LOH loci may be associated with pathologic progression in recurrent phyllodes tumors.
  • In a single case of phyllodes tumor containing a malignant epithelial component the malignant epithelium and stroma partially share an LOH genotype, suggesting a common precursor cell for the biphasic malignant components.
  • [MeSH-major] Breast Neoplasms / genetics. Fibroadenoma / genetics. Loss of Heterozygosity. Neoplasms, Multiple Primary / genetics. Neoplasms, Second Primary / genetics. Oligonucleotide Array Sequence Analysis. Phyllodes Tumor / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Cell Transformation, Neoplastic / genetics. DNA, Neoplasm / genetics. Epithelial Cells / pathology. Female. Gene Expression Profiling. Genome, Human. Humans. Stromal Cells / pathology

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16791486.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / NCI P50 CA89393-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


42. Thamboo TP, Sim R, Tan SY, Yap WM: Primary retroperitoneal mucinous cystadenocarcinoma in a male patient. J Clin Pathol; 2006 Jun;59(6):655-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 64-year-old man presented with a large retroperitoneal cystic tumour measuring 24 x 20 x 16 cm3, which was removed intact.
  • Areas ranging from a benign mucinous cyst to borderline mucinous tumour to mucinous cystadenocarcinoma were observed on microscopy.
  • Strong patchy staining for cytokeratins 7 and 20 and strong diffuse staining for MUC2 and MUC5AC core peptides, similar to staining patterns in ovarian mucinous tumours, were shown in the benign and atypical epithelium.
  • The theory of its origin from the mucinous metaplasia of peritoneal (mesothelial) inclusion cysts, rather than from ectopic ovarian tissue or ovarian teratomas, is supported by the occurrence of such a tumour in a male patient.
  • [MeSH-minor] Humans. Keratins / metabolism. Male. Middle Aged. Mucins / metabolism. Neoplasm Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2000 Jun;31(6):672-7 [10872659.001]
  • [Cites] Arch Pathol Lab Med. 2001 May;125(5):691-4 [11300948.001]
  • [Cites] Surg Today. 2001;31(8):747-50 [11510618.001]
  • [Cites] Int J Gynecol Pathol. 2002 Oct;21(4):391-400 [12352188.001]
  • [Cites] Hinyokika Kiyo. 2003 Mar;49(3):145-7 [12728527.001]
  • [Cites] Gynecol Oncol. 1991 Jul;42(1):64-7 [1717354.001]
  • [Cites] APMIS. 1991 Nov;99(11):1055-7 [1958350.001]
  • [Cites] Acta Cytol. 1994 Mar-Apr;38(2):261-6 [8147222.001]
  • [Cites] Hum Pathol. 1994 Apr;25(4):364-72 [8163269.001]
  • [Cites] Gynecol Oncol. 1994 Nov;55(2):308-12 [7959300.001]
  • [Cites] Virchows Arch. 1994;424(1):53-7 [7981904.001]
  • [Cites] Eur J Surg. 1991 Oct;157(10):621-2 [1687258.001]
  • [Cites] Virchows Arch. 1995;426(6):641-5 [7655747.001]
  • [Cites] Clin Imaging. 1996 Apr-Jun;20(2):129-32 [8744823.001]
  • [Cites] J Pathol. 1997 Aug;182(4):385-91 [9306958.001]
  • (PMID = 16731606.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Mucins; 0 / Neoplasm Proteins; 68238-35-7 / Keratins
  • [Number-of-references] 15
  • [Other-IDs] NLM/ PMC1860402
  •  go-up   go-down


43. Lee SH, Lee DS, You IY, Jeon WJ, Park SM, Youn SJ, Choi JW, Sung R: [Histopathologic analysis of adenoma and adenoma-related lesions of the gallbladder]. Korean J Gastroenterol; 2010 Feb;55(2):119-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Among 1,847 cholecystectomized specimens, 63 specimens from 26 benign adenomas, 9 carcinomas in situ (CIS), and 28 invasive carcinomas were selected.
  • A pathologist reviewed all specimens and selected benign adenomas, CIS in the adenoma, and adenoma residue in invasive carcinomas.
  • Adenomas and adenoma-related lesions were classified according to morphology (tubular, tubulopapillary, and papillary) and the consisting epithelium (biliary, pyloric metaplasia, and intestinal metaplasia).
  • The age and the size of the benign adenomas and carcinomas in the adenoma were also compared.
  • All eight carcinomas arising in the adenoma were well-differentiated solitary tumors.
  • The diameters of the carcinomas in the adenoma were, on average, larger than that of the benign adenomas (1.8 cm vs. 0.9 cm, p=0.01).
  • The patients with carcinomas in the adenoma were, on average, older than those with benign adenomas, although the difference was insignificant (57 years vs. 47 years, p=0.09).
  • The morphology and consisting epithelium did not differ between the benign adenomas and carcinomas in the adenoma.
  • [MeSH-minor] Adult. Age Factors. Aged. Carcinoma / epidemiology. Carcinoma / pathology. Carcinoma / surgery. Cell Transformation, Neoplastic. Cholecystectomy. Cystadenoma / epidemiology. Cystadenoma / pathology. Cystadenoma / surgery. Female. Gallstones / complications. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20168058.001).
  • [ISSN] 2233-6869
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


44. Desjardins L: [Choroidal nevi]. J Fr Ophtalmol; 2010 Feb;33(2):136-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe the clinical, angiographic, and echographic aspects of benign choroidal nevi and their differential diagnosis represented mostly by congenital hypertrophy of the pigment epithelium, melanocytoma, and mostly suspicious nevi.
  • [MeSH-minor] Aftercare. Diagnosis, Differential. Fluorescein Angiography. Humans. Melanoma / diagnosis. Neoplasm Staging. Ophthalmoscopy. Prognosis. Risk Factors. Tomography, Optical Coherence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20116886.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


45. Ødegaard E, Staff AC, Kaern J, Flørenes VA, Kopolovic J, Tropé CG, Abeler VM, Reich R, Davidson B: The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma. Gynecol Oncol; 2006 Mar;100(3):462-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To analyze the expression of the AP-2gamma transcription factor in ovarian borderline tumors, early-stage ovarian carcinoma and advanced-stage ovarian carcinoma, and to evaluate its prognostic role in advanced-stage tumors.
  • METHODS: Sections from 14 normal ovaries, 75 borderline tumors, 22 FIGO stage I invasive ovarian carcinomas, and 306 advanced-stage (FIGO stages II-IV) ovarian carcinomas (42 primary tumors, 62 solid metastases, 202 effusions) were evaluated for expression of the transcription factor AP-2gamma using immunohistochemistry.
  • RESULTS: AP-2gamma was detected in the nucleus of tumor cells in 28/75 (37%) borderline tumors, 13/22 (59%) FIGO stage I carcinomas, and 255/306 (83%) advanced-stage carcinomas (P < 0.001, Chi-square test).
  • Benign ovaries were uniformly negative.
  • CONCLUSIONS: AP-2gamma expression is upregulated in advanced-stage ovarian carcinoma compared to early-stage carcinomas, borderline tumors, and the ovarian surface epithelium, and AP-2gamma is specifically localized to cancer cells in effusions, suggesting a role in tumor progression.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Nucleus / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Neoplasm Staging. Proto-Oncogene Proteins c-kit / metabolism. Up-Regulation

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16216317.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Transcription Factor AP-2; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


46. Kato N, Sasou S, Motoyama T: Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol; 2006 Jan;19(1):83-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary.
  • Clear cell tumors of the ovary are frequently associated with ovarian endometriosis.
  • Clinicopathologically, it has been suggested that clear cell tumors develop from endometriosis, but there has been little molecular evidence supporting this speculation.
  • In the present study, we examined 30 clear cell tumors (26 malignant, three borderline, and one benign) and 40 endometriotic cysts to clarify if differentiation into the clear cell lineage already begins in ovarian endometriosis.
  • All of the 30 clear cell tumors, including borderline and benign ones, showed immunohistochemical expression of HNF-1beta in the nucleus, while other types of ovarian epithelial tumors (endometrioid, serous, mucinous, and Brenner tumors) rarely expressed it.
  • Among 30 clear cell tumors, 17 (56%) cases were associated with endometriosis, and endometriotic epithelium was identified in 12 cases.
  • In nine of the 12 cases, distinct nuclear immunostaining for HNF-1beta was detected in the endometriotic epithelium, as well as in the clear cell tumor.
  • Furthermore, 16 of 40 (40%) endometriotic cysts without a neoplasm also expressed HNF-1beta, and the expression was almost exclusively observed in the epithelium showing inflammatory atypia.
  • Our results indicate that HNF-1beta is an excellent molecular marker for ovarian clear cell tumors, including benign, borderline and malignant lesions.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Endometriosis / pathology. Hepatocyte Nuclear Factor 1-beta / biosynthesis. Ovarian Diseases / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Epithelial Cells / chemistry. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Ovarian Cysts / metabolism. Ovarian Cysts / pathology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258507.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 138674-15-4 / Hepatocyte Nuclear Factor 1-beta
  •  go-up   go-down


47. Sabbisetti V, Chigurupati S, Thomas S, Shah G: Calcitonin stimulates the secretion of urokinase-type plasminogen activator from prostate cancer cells: its possible implications on tumor cell invasion. Int J Cancer; 2006 Jun 1;118(11):2694-702
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcitonin stimulates the secretion of urokinase-type plasminogen activator from prostate cancer cells: its possible implications on tumor cell invasion.
  • Calcitonin (CT) is synthesized and secreted in prostate epithelium, and its secretion from malignant prostates is several folds higher than that in benign prostates.
  • CT receptor (CTR) is expressed in malignant prostate epithelium, and its activation increases invasiveness of prostate cancer (PC) cells via activation of protein kinase A.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. Calcitonin .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16381004.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA096534; United States / NCI NIH HHS / CA / CA96534
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-12-9 / Calcitonin; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator; EC 3.4.24.- / Gelatinases
  •  go-up   go-down


48. Bettendorf O, Schmidt H, Staebler A, Grobholz R, Heinecke A, Boecker W, Hertle L, Semjonow A: Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate. Genes Chromosomes Cancer; 2008 Jul;47(7):565-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of the present study was to analyze the genetic relationship between benign prostatic tissue, PIN, invasive cancer, IDC-P, and extracapsular tumor tissue to get further information about the role of IDC-P in the development of prostate cancer.
  • One hundred five radical prostatectomy specimens were investigated immunohistochemically, 77 cases were analyzed by PCR for LOH of the tumor suppressor genes TP53 and RB1, and 11 cases of IDC-P and 10 cases of PIN were investigated using comparative genomic hybridization (CGH).
  • We could demonstrate a significant increase of LOH for TP53 or RB1 from benign tissue to PIN.
  • LOH of both TP53 and RB1 were frequently found in IDC-P (52%), followed by extracapsular tumor tissue (44%), invasive cancer (24%), PIN (19%), and benign prostatic tissue (17%).
  • Decreased expression could be demonstrated in extracapsular tumor tissue and in IDC-P.
  • Our results indicate that IDC-P in general follows the genetic pathway from normal epithelium over PIN lesion.
  • [MeSH-major] Chromosomal Instability. Loss of Heterozygosity. PTEN Phosphohydrolase / metabolism. Prostatic Neoplasms / genetics. Prostatic Neoplasms / metabolism. Retinoblastoma Protein / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Aged. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Carcinoma, Intraductal, Noninfiltrating / genetics. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Prostatic Intraepithelial Neoplasia / genetics. Prostatic Intraepithelial Neoplasia / metabolism. Prostatic Intraepithelial Neoplasia / pathology


49. Glen A, Gan CS, Hamdy FC, Eaton CL, Cross SS, Catto JW, Wright PC, Rehman I: iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression. J Proteome Res; 2008 Mar;7(3):897-907
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Differential expression of brain creatine kinase (CKBB), soluble catechol-O-methyltransferase (S-COMT), tumor rejection antigen (gp96), and glucose regulated protein, 78 kDa (grp78), was confirmed by Western blotting or independent 2D-PAGE analysis.
  • The clinical relevance of gp96 was assessed by immunohistochemistry using prostate tissues from benign ( n = 95), malignant ( n = 66), and metastatic cases ( n = 3).
  • Benign epithelium showed absent/weak gp96 expression in the basal cells, in contrast to the moderate/strong expression seen in malignant epithelium.
  • Furthermore, there was a statistically significant difference in the intensity of gp96 expression between benign and malignant cases ( p < 0.0005, Mann-Whitney U).
  • [MeSH-major] Neoplasm Proteins / metabolism. Prostatic Neoplasms / metabolism. Proteomics
  • [MeSH-minor] Cell Line, Tumor. Chromatography, Liquid. Disease Progression. Electrophoresis, Gel, Two-Dimensional. Humans. Immunohistochemistry. Male. Reproducibility of Results. Spectrometry, Mass, Electrospray Ionization / methods


50. De Riu G, Meloni SM, Contini M, Tullio A: Ameloblastic fibro-odontoma. Case report and review of the literature. J Craniomaxillofac Surg; 2010 Mar;38(2):141-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ameloblastic fibro-odontoma (AFO) is defined by the World Health Organization (WHO) as a neoplasm composed of proliferating odontogenic epithelium.
  • It is a benign, slow-growing, expansive tumour that clinically appears as a well-encapsulated, benign lesion.

  • Genetic Alliance. consumer health - Odontoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20185068.001).
  • [ISSN] 1878-4119
  • [Journal-full-title] Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
  • [ISO-abbreviation] J Craniomaxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Scotland
  • [Number-of-references] 27
  •  go-up   go-down


51. Cagle PT, Churg A: Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies. Arch Pathol Lab Med; 2005 Nov;129(11):1421-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies.
  • CONTEXT: Although much of the pathology literature focuses on differential diagnosis of diffuse malignant mesothelioma from other types of cancer, the primary diagnostic challenge facing the pathologist is often whether a mesothelial proliferation on a pleural biopsy represents a malignancy or a benign reactive hyperplasia.
  • DESIGN: Based on previous medical publications, extensive personal consultations, and experience on the United States-Canadian Mesothelioma Reference Panel and the International Mesothelioma Panel, salient information was determined about interpretation of benign versus malignant mesothelial proliferations on pleural biopsies.
  • RESULTS: Differentiation of benign reactive mesothelial hyperplasia from diffuse malignant mesothelioma is often difficult.
  • Benign reactive mesothelial hyperplasia may mimic many features ordinarily associated with malignancy, and diffuse malignant mesothelioma may be cytologically bland.
  • Entrapment of benign reactive mesothelial cells within organizing pleuritis may mimic tissue invasion.
  • CONCLUSIONS: Various histologic clues favor a benign over a malignant mesothelial proliferation and vice versa.
  • [MeSH-major] Epithelium / pathology. Mesothelioma / pathology. Pleura / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Humans. Hyperplasia / pathology. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253023.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


52. Siar CH, Nakano K, Han PP, Nagatsuka H, Ng KH, Kawakami T: Differential expression of Notch receptors and their ligands in desmoplastic ameloblastoma. J Oral Pathol Med; 2010 Aug 1;39(7):552-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The ameloblastoma, a benign odontogenic epithelial neoplasm, histologically recapitulates the enamel organ at bell stage.
  • RESULTS: Ameloblastoma tumor epithelium demonstrated positive expression for Notch1 (n = 5/10), Notch3 (n = 8/10), Notch4 (n = 10/10), Jagged1 (n = 6/10) and Delta1 (n = 5/10), but no reactivity for Notch2 (n = 10/10) and Jagged2 (10/10).
  • Positive activity was detected largely in the cell membrane and cytoplasm of peripheral and central neoplastic epithelial cells, and sometimes in the nucleus.
  • [MeSH-minor] Adult. Calcium-Binding Proteins / analysis. Cell Membrane / ultrastructure. Cell Nucleus / ultrastructure. Cytoplasm / ultrastructure. Endothelial Cells / pathology. Epithelial Cells / pathology. Epithelium / pathology. Female. Fibroblasts / pathology. Gene Expression Regulation, Neoplastic / genetics. Humans. Immunohistochemistry. Intercellular Signaling Peptides and Proteins / analysis. Intracellular Signaling Peptides and Proteins. Ligands. Male. Mandibular Neoplasms / pathology. Maxillary Neoplasms / pathology. Membrane Proteins / analysis. Middle Aged. Proto-Oncogene Proteins / analysis. Receptor, Notch1 / analysis. Receptor, Notch2 / analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20337864.001).
  • [ISSN] 1600-0714
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / JAG2 protein, human; 0 / Ligands; 0 / Membrane Proteins; 0 / NOTCH1 protein, human; 0 / NOTCH2 protein, human; 0 / NOTCH3 protein, human; 0 / NOTCH4 protein, human; 0 / Proto-Oncogene Proteins; 0 / Receptor, Notch1; 0 / Receptor, Notch2; 0 / Receptors, Notch; 0 / delta protein; 134324-36-0 / Serrate proteins
  •  go-up   go-down


53. Mendrinos S, Nolen JD, Styblo T, Carlson G, Pohl J, Lewis M, Ritchie J: Cytologic findings and protein expression profiles associated with ductal carcinoma of the breast in ductal lavage specimens using surface-enhanced laser desorption and ionization-time of flight mass spectrometry. Cancer; 2005 Jun 25;105(3):178-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Only 5 of 16 DL specimens (31%) from breasts with biopsy-proven carcinoma contained malignant cells, whereas the remaining samples contained only histiocytes and clusters of benign ductal epithelium.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal / pathology. Neoplasm Proteins / analysis. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods
  • [MeSH-minor] BRCA1 Protein / analysis. BRCA2 Protein / analysis. Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Case-Control Studies. Cytodiagnosis / methods. Female. Humans. Immunohistochemistry. Nipples / cytology. Sampling Studies. Sensitivity and Specificity. Tissue Culture Techniques

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15822128.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BRCA1 Protein; 0 / BRCA2 Protein; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


54. Corzo C, Corominas JM, Tusquets I, Salido M, Bellet M, Fabregat X, Serrano S, Solé F: The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma. Cancer Genet Cytogenet; 2006 Mar;165(2):151-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma.
  • One hypothesis for breast cancer development suggests that breast carcinogenesis involves a progression of events leading from benign epithelium to hyperplasia (with or without atypia) to carcinoma in situ and then invasive carcinoma.
  • Benign lesions and normal adjacent cells were classified as normal.
  • The presence of MYC amplification only in invasive cells suggests that the finding of MYC amplification could reflect an advanced tumor progression.
  • [MeSH-minor] Chromosomes, Human, Pair 8. Disease Progression. Female. Humans. In Situ Hybridization, Fluorescence. Neoplasm Invasiveness. Paraffin Embedding

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527609.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


55. Esposito NN, Mohan D, Brufsky A, Lin Y, Kapali M, Dabbs DJ: Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases. Arch Pathol Lab Med; 2006 Oct;130(10):1516-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases.
  • CONTEXT: Phyllodes tumors (PTs) of the breast are biphasic neoplasms composed of epithelium and a spindle-cell stroma.
  • Currently, PTs are classified as benign, borderline, or malignant based on histopathologic features.
  • However, histologic classification does not always predict outcome.
  • DESIGN: Sixteen benign, 8 borderline, and 6 malignant PTs with follow-up were examined for reactivity across a panel of immunohistochemical stains, including c-Kit, endothelin 1, p16, p21, p53, and Ki-67.
  • Tumor variables were compared among tumor subgroups and between tumors that did and did not recur.
  • RESULTS: Of the 30 PTs, 4 recurred (1 benign, 2 borderline, 1 malignant).
  • One patient with a malignant tumor died of metastatic disease 34 months after initial diagnosis.
  • The overall positive rate of c-Kit immunoreactivity was 13% in benign, 63% in borderline, and 67% in malignant PTs.
  • Endothelin 1 epithelial cytoplasmic staining was seen in 100% of benign, 50% of borderline, and 17% of malignant PTs.
  • Additionally, p16, p21, p53, and Ki-67 were differentially expressed among benign, borderline, and malignant tumors.
  • CONCLUSIONS: Stromal c-Kit positivity and epithelial endothelin 1 negativity are more often associated with malignant PTs; however, only positive margin status is significantly associated with tumor behavior.
  • [MeSH-major] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Phyllodes Tumor / metabolism. Phyllodes Tumor / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Disease Progression. Endothelin-1 / metabolism. Epithelium / metabolism. Female. Humans. Immunohistochemistry / methods. Ki-67 Antigen / metabolism. Mastectomy. Mastectomy, Segmental. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Proto-Oncogene Proteins c-kit / metabolism. Staining and Labeling. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17090194.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Endothelin-1; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


56. Wang Q, Zhang P, Zhang Q, Wang X, Li J, Ma C, Sun W, Zhang L: Analysis of CD137 and CD137L expression in human primary tumor tissues. Croat Med J; 2008 Apr;49(2):192-200
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of CD137 and CD137L expression in human primary tumor tissues.
  • AIM: To assess the expression of CD137 and CD137L in human primary tumor tissues and their potential role in tumor immunity.
  • METHODS: Expression of CD137 and CD137L was assessed by immunohistochemistry in frozen sections of 12 human normal tissues, 15 benign tumors of epithelial or mesenchymal origin (adenoma and leiomyoma), and 36 malignant tumors of epithelial origin (squamous cell carcinoma and adenocarcinoma).
  • The expression of CD137L on 9 human tumor cell lines (3 hepatocarcinoma, 2 lung carcinoma, 2 colon carcinoma, 1 lymphoma, and 1 leukemia) was detected by reverse transcription polymerase chain reaction.
  • To analyze the role of CD137L expressed on tumor cells, we co-cultured tumor cells expressing CD137L with activated T lymphocytes expressing CD137 or with Chinese hamster ovary cells expressing CD137 and then detected by ELISA the levels of cytokines (IL-8, IFN-gamma) secreted by tumor cells or activated T cells.
  • RESULTS: The expression of CD137 and CD137L was observed only in human benign (2/15, 3/15) or malignant tumors (15/36, 21/36), but not in normal tissues (0/12, 0/12).
  • CD137 was expressed on the vessel walls within tumor tissues, whereas CD137L was expressed on tumor cells.
  • The expression of CD137 and CD137L was more common in malignant tumors, especially in moderate or low-differentiated tumors.
  • Furthermore, CD137L expression found on tumor cell lines was functional because the ligation of CD137L on lung squamous carcinoma cells L78 with CD137 on T cells induced IFN-gamma production by T cells, and ligation of CD137L on hepatocarcinoma cells HepG2.2.15 with CD137 triggered tumor cells to produce IL-8.
  • CONCLUSION: CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors.
  • [MeSH-minor] Cell Line, Tumor. Disease Progression. Humans. Immunohistochemistry. Signal Transduction. Tumor Cells, Cultured

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Immunol Ther Exp (Warsz). 1999;47(5):275-9 [10604232.001]
  • [Cites] J Immunol. 2000 Sep 1;165(5):2903-10 [10946324.001]
  • [Cites] Am J Clin Pathol. 2001 Apr;115(4):543-9 [11293902.001]
  • [Cites] J Immunol. 2001 Aug 1;167(3):1313-24 [11466348.001]
  • [Cites] J Immunol. 2002 May 15;168(10):4897-906 [11994439.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3459-65 [12067989.001]
  • [Cites] Eur J Immunol. 2002 Dec;32(12):3617-27 [12516549.001]
  • [Cites] Cell Immunol. 2003 Nov;226(1):37-44 [14746806.001]
  • [Cites] Transpl Int. 2004 Aug;17(7):351-61 [15349720.001]
  • [Cites] Blood. 1995 Feb 15;85(4):1043-52 [7849293.001]
  • [Cites] J Immunol. 1995 Oct 1;155(7):3360-7 [7561030.001]
  • [Cites] J Immunol. 1998 Mar 1;160(5):2488-94 [9498794.001]
  • [Cites] J Exp Med. 1998 Jun 1;187(11):1849-62 [9607925.001]
  • [Cites] Semin Immunol. 1998 Dec;10(6):481-9 [9826581.001]
  • [Cites] J Leukoc Biol. 2005 Mar;77(3):281-6 [15618293.001]
  • [Cites] Annu Rev Immunol. 2005;23:23-68 [15771565.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):122-33 [15831231.001]
  • [Cites] J Immunother. 2005 Sep-Oct;28(5):449-60 [16113601.001]
  • [Cites] Hum Gene Ther. 2006 Aug;17(8):798-806 [16942440.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2758-67 [17460060.001]
  • [Cites] J Immunol. 2007 Oct 1;179(7):4910-8 [17878391.001]
  • (PMID = 18461674.001).
  • [ISSN] 1332-8166
  • [Journal-full-title] Croatian medical journal
  • [ISO-abbreviation] Croat. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / 4-1BB Ligand; 0 / Antigens, CD137
  • [Other-IDs] NLM/ PMC2359873
  •  go-up   go-down


57. Chetty R, Serra S: Intraductal tubular adenoma (pyloric gland-type) of the pancreas: a reappraisal and possible relationship with gastric-type intraductal papillary mucinous neoplasm. Histopathology; 2009 Sep;55(3):270-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal tubular adenoma (pyloric gland-type) of the pancreas: a reappraisal and possible relationship with gastric-type intraductal papillary mucinous neoplasm.
  • Three cases of ITA are presented, the literature reviewed and their association with intraductal papillary mucinous neoplasm (IPMN) is postulated.
  • METHODS AND RESULTS: ITA is composed of tightly packed tubular structures with focal cystic dilation and papillary areas lined by gastric/pyloric epithelium showing minimal to mild cytological atypia.
  • The coexistence of ITA and IPMN and the similarities of their epithelial lining (gastric/pyloric mucosa) suggest a possible pathogenic link.
  • ITA could represent a localized, polypoid form of gastric-type IPMN.It is a benign lesion with no evidence of invasion and no direct tumour-related deaths.
  • [MeSH-minor] Aged. Epithelial Cells / pathology. Female. Humans. Male. Middle Aged. Neoplasms, Multiple Primary. Pancreatectomy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Histopathology. 2010 Jun;56(7):968-9; author reply 969 [20636797.001]
  • (PMID = 19723141.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


58. Kuivanen TT, Jeskanen L, Kyllönen L, Impola U, Saarialho-Kere UK: Transformation-specific matrix metalloproteinases, MMP-7 and MMP-13, are present in epithelial cells of keratoacanthomas. Mod Pathol; 2006 Sep;19(9):1203-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transformation-specific matrix metalloproteinases, MMP-7 and MMP-13, are present in epithelial cells of keratoacanthomas.
  • Keratoacanthomas are rapidly growing hyperproliferative skin tumors that may clinically or histologically be difficult to distinguish from well-differentiated squamous cell cancers (SCCs).
  • In situ hybridization for MMP-7, -10, and -13 was performed in a subset of tumors.
  • MMP-7 was present in the epithelium of 4/31 keratoacanthomas and 9/15 SCCs, MMP-8 in 3/30 keratoacanthomas and 0/15 SCCs, but MMP-13 in 16/31 keratoacanthomas and 10/15 SCCs, and MMP-10 in 28/31 keratoacanthomas and all cancers.
  • MMP-9 was detected in the epithelium in 5/31 keratoacanthomas and 8/15 SCCs, whereas MMP-2 was only present in fibroblasts in both tumors.
  • MMP-19 was upregulated in proliferating epithelium of keratoacanthomas as was p16.
  • We conclude that although some MMPs (MMP-10 and -13) are abundantly expressed in keratoacanthomas, the presence of MMP-7 and -9 in their epithelial pushing border is rare and should raise suspicion of SCC.
  • Frequent expression of the transformation-specific MMP-13 in keratoacanthomas suggests that they are not benign tumors but incomplete SCCs.
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Diagnosis, Differential. Female. Fibroblasts / enzymology. Fibroblasts / pathology. Humans. In Situ Hybridization. Male. Matrix Metalloproteinase 13. Middle Aged. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published online 12 May 2006.
  • (PMID = 16699496.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Neoplasm Proteins; 0 / RNA, Messenger; EC 3.4.24.- / Collagenases; EC 3.4.24.- / MMP13 protein, human; EC 3.4.24.- / Matrix Metalloproteinase 13; EC 3.4.24.23 / MMP7 protein, human; EC 3.4.24.23 / Matrix Metalloproteinase 7
  •  go-up   go-down


59. Katona TM, Neubauer BL, Iversen PW, Zhang S, Baldridge LA, Cheng L: Elevated expression of angiogenin in prostate cancer and its precursors. Clin Cancer Res; 2005 Dec 1;11(23):8358-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we have investigated the expression of angiogenin in prostatic adenocarcinoma, high-grade prostatic intraepithelial neoplasia, and adjacent benign prostatic epithelium in a large cohort of prostatectomy specimens.
  • METHODS: We have studied the expression of angiogenin by immunohistochemistry in prostatic adenocarcinoma, high-grade prostatic intraepithelial neoplasia, and adjacent benign prostatic tissue in 107 human total prostatectomy specimens.
  • RESULTS: The percentage of cells staining positively for angiogenin in benign prostatic glandular epithelium (mean = 17%) was significantly less than for high-grade prostatic intraepithelial neoplasia (mean = 58%, P < 0.001) and prostatic adenocarcinoma (mean = 60%, P < 0.001).
  • Compared with adjacent benign prostatic epithelium, the staining intensity was significantly greater in high-grade prostatic intraepithelial neoplasia (P < 0.001) and prostatic adenocarcinoma (P < 0.001).
  • However, there was no correlation of angiogenin expression with various clinical and pathologic variables examined, including age at surgery, Gleason scores, pathologic stage, tumor extent, angiolymphatic invasion, extraprostatic extension, seminal vesical invasion, lymph node metastasis, surgical margin status, presence of prostatic intraepithelial neoplasia, and perineural invasion.
  • CONCLUSION: Angiogenin expression in prostatic tissue increases as prostatic epithelial cells evolve from a benign to an invasive phenotype.
  • The increasing expression of prostatic adenocarcinoma in the progression from benign prostate to high-grade prostatic intraepithelial neoplasia and ultimately to prostatic adenocarcinoma are consistent with previous studies showing the influential role that angiogenin plays in the growth, invasion, and metastasis of prostatic adenocarcinoma and many other malignant tumors.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Enzyme-Linked Immunosorbent Assay. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Prostatectomy. Prostatic Hyperplasia / metabolism. Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / surgery. Prostatic Intraepithelial Neoplasia / metabolism. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Intraepithelial Neoplasia / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16322296.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.1.27.- / angiogenin; EC 3.1.27.5 / Ribonuclease, Pancreatic
  •  go-up   go-down


60. Risk MC, Knudsen BS, Coleman I, Dumpit RF, Kristal AR, LeMeur N, Gentleman RC, True LD, Nelson PS, Lin DW: Differential gene expression in benign prostate epithelium of men with and without prostate cancer: evidence for a prostate cancer field effect. Clin Cancer Res; 2010 Nov 15;16(22):5414-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential gene expression in benign prostate epithelium of men with and without prostate cancer: evidence for a prostate cancer field effect.
  • BACKGROUND: Several malignancies are known to exhibit a "field effect," whereby regions beyond tumor boundaries harbor histologic or molecular changes that are associated with cancer.
  • We sought to determine if histologically benign prostate epithelium collected from men with prostate cancer exhibits features indicative of premalignancy or field effect.
  • Benign epithelia from each patient were isolated by laser capture microdissection.
  • RESULTS: Overall patterns of gene expression in microdissected benign prostate-associated benign epithelium (BABE) and cancer-associated benign epithelium (CABE) were similar.
  • CONCLUSION: Gene expression profiles between benign epithelia of patients with and without prostate cancer are very similar.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8337-41 [16951139.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 15;98(4):255-61 [16478744.001]
  • [Cites] BMC Urol. 2007;7:3 [17335564.001]
  • [Cites] Prostate. 2007 May 15;67(7):714-21 [17342744.001]
  • [Cites] Scand J Urol Nephrol. 2007;41(2):85-90 [17454944.001]
  • [Cites] JAMA. 2007 Jun 6;297(21):2351-9 [17551129.001]
  • [Cites] Prostate. 2008 Feb 1;68(2):152-60 [18058812.001]
  • [Cites] Mod Pathol. 2008 Feb;21(2):67-75 [18065961.001]
  • [Cites] Clin Cancer Res. 2008 Mar 15;14(6):1734-43 [18347174.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3584-90 [18483239.001]
  • [Cites] Clin Cancer Res. 2008 Jun 1;14(11):3395-400 [18519769.001]
  • [Cites] Clin Cancer Res. 2009 Jun 15;15(12):3979-89 [19509179.001]
  • [Cites] Eur Urol. 2009 Apr;55(4):885-90 [18501497.001]
  • [Cites] Prostate. 2009 Sep 15;69(13):1470-9 [19462462.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jul;85(7):2564-71 [10902809.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] J Urol. 2001 Nov;166(5):1679-83 [11586201.001]
  • [Cites] Urology. 2002 Aug;60(2):264-9 [12137824.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4427-33 [12154050.001]
  • [Cites] Prostate. 2003 Apr 1;55(1):71-80 [12640663.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1727-30 [12702551.001]
  • [Cites] Hum Pathol. 2003 May;34(5):450-6 [12792918.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5879-88 [14522913.001]
  • [Cites] Cancer. 2004 Jun 1;100(11):2362-6 [15160339.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2573-6 [15197798.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4096-100 [15217945.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2790-9 [15254046.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1543-56 [15509525.001]
  • [Cites] Cancer. 1972 Jul;30(1):5-13 [5064808.001]
  • [Cites] J Urol. 1994 Jun;151(6):1571-4 [7514690.001]
  • [Cites] Int J Cancer. 1995 Sep 4;62(5):552-8 [7665226.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Sep;80(9):2806-14 [7673428.001]
  • [Cites] Prostate. 1997 Jun 15;32(1):59-64 [9207958.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Aug;82(8):2566-9 [9253335.001]
  • [Cites] Urology. 1998 Oct;52(4):637-40 [9763084.001]
  • [Cites] Clin Cancer Res. 1996 Sep;2(9):1445-51 [9816319.001]
  • [Cites] Clin Cancer Res. 1997 Jan;3(1):81-5 [9815541.001]
  • [Cites] Prostate. 1999 Sep 15;41(1):12-9 [10440871.001]
  • [Cites] Oncogene. 2005 May 26;24(23):3847-52 [15750627.001]
  • [Cites] Prostate. 2005 Jun 1;63(4):341-6 [15602744.001]
  • [Cites] BMC Cancer. 2005;5:45 [15892885.001]
  • [Cites] J Urol. 2005 Aug;174(2):514-8 [16006883.001]
  • [Cites] Mod Pathol. 2005 Aug;18(8):1022-6 [15861213.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Prostate. 2006 Jun 1;66(8):867-75 [16496414.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):10991-6 [16829574.001]
  • [Cites] J Clin Oncol. 2006 Aug 10;24(23):3763-70 [16822846.001]
  • [Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]
  • [Cites] Eur Urol. 2005 Dec;48(6):895-9 [16125298.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2628-36 [17083125.001]
  • (PMID = 20935156.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA97186; United States / NCI NIH HHS / CA / CA097186-06; United States / NCI NIH HHS / CA / P30 CA015704; United States / NCI NIH HHS / CA / P50 CA097186; United States / NCI NIH HHS / CA / P50 CA097186-06; United States / NIDDK NIH HHS / DK / K23 DK065083-05; United States / NIDDK NIH HHS / DK / K23 DK065083; United States / NIDDK NIH HHS / DK / DK065083-05; United States / NIDDK NIH HHS / DK / DK65083
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ERG protein, human; 0 / Trans-Activators; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / TMPRSS2 protein, human
  • [Other-IDs] NLM/ NIHMS243127; NLM/ PMC2992073
  •  go-up   go-down


61. Chen XD, Shi HY, Zhang XF: [Clinicopathologic analysis of 102 cases of mixed epithelial and mesenchymal tumors of the uterus]. Zhonghua Fu Chan Ke Za Zhi; 2007 Apr;42(4):219-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic analysis of 102 cases of mixed epithelial and mesenchymal tumors of the uterus].
  • OBJECTIVE: To study the clinical and pathologic features, histological criteria and pathologic factors contributing to diagnosis of mixed epithelial and mesenchymal tumors (mixed müllerian tumors, MMT) of the uterus.
  • Benign MMT usually presented as exophytic polypoid masses extending into the uterine cavity or protruding through the external os, often broad-based, lobulated and papillary.
  • It was hard to distinguish low-grade malignant MMT from the benign ones by gross appearance.
  • Histologically, MMT showed a biphasic differentiation of mesenchymal and epithelial components.
  • MMT were classified according to whether these elements were benign or malignant.
  • Recurrent tumors were almost always confined to the original site.
  • CONCLUSIONS: Uterine MMT tumors according to WHO diagnostic criteria are not rare.
  • The recurrent adenofibromas may be a kind of borderline tumors with benign appearances and malignant behavior.
  • [MeSH-major] Mixed Tumor, Mullerian / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adenofibroma / pathology. Adenomyoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Epithelium / pathology. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17631758.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


62. Rosner IL, Ravindranath L, Furusato B, Chen Y, Gao C, Cullen J, Sesterhenn IA, McLeod DG, Srivastava S, Petrovics G: Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy. Urology; 2007 Dec;70(6):1225-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy.
  • Because AR mutations or amplification are rare in early stage CaP, we hypothesized that altered AR expression in prostate tumor cells may provide a prognostic indicator of disease progression.
  • METHODS: RNA from laser capture microdissected (LCM) tumor and benign epithelial cells from radical prostatectomy specimens of 115 hormone-naive patients were studied.
  • A ratio of the expression of AR gene, normalized to GAPDH gene expression in the same specimens, was compared in tumor and benign epithelial cells (tumor-to-benign ratio) and correlated with clinicopathologic features.
  • RESULTS: Paired t test analysis revealed a 62% lower AR expression in tumor tissue compared with benign tissue (P = 0.0005).
  • However, multivariate Cox proportional hazards regression analysis of time to PSA recurrence revealed that higher tumor cell associated AR expression (continuous, log-transformed), significantly increases odds of prostate-specific antigen (PSA) recurrence (P = 0.0139) when controlling for age at surgery, race, time from diagnosis to surgery, risk stratification, pathologic T stage, Gleason sum, and margin status.
  • CONCLUSIONS: Quantitative determination of AR gene expression levels in prostate epithelial cells may be useful for predicting PSA recurrence.


63. Virk R, Lu D: Mucinous adenocarcinoma as heterologous element in intermediately differentiated Sertoli-Leydig cell tumor of the ovary. Pathol Res Pract; 2010 Jul 15;206(7):489-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma as heterologous element in intermediately differentiated Sertoli-Leydig cell tumor of the ovary.
  • Sertoli-Leydig cell tumor (SLCT) is a rare tumor involving the ovary.
  • The gastrointestinal-type epithelium is the most commonly described endodermal heterologous element.
  • SLCT with benign and borderline mucinous neoplasm has been reported in the literature.
  • Herein, we describe a rare case of intermediately differentiated Sertoli-Leydig cell tumor with mucinous adenocarcinoma as the heterologous element in a 21-year-old woman.
  • Microscopically, the tumor was composed of intermediately differentiated Sertoli-Leydig cell tumor and well-differentiated mucinous adenocarcinoma.
  • Interestingly, the bulk of the tumor (more than 90%) was composed of mucinous adenocarcinoma, whereas the SLCT component comprised less than 10% of the total tumor.
  • This case was a diagnostic challenge as more than 90% of the tumor was composed of mucinous adenocarcinoma and SLCT constituted only the minor part of the tumor.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology. Sertoli-Leydig Cell Tumor / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009. Published by Elsevier GmbH.
  • (PMID = 19674851.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


64. Yang K, Tang Y, Habermehl GK, Iczkowski KA: Stable alterations of CD44 isoform expression in prostate cancer cells decrease invasion and growth and alter ligand binding and chemosensitivity. BMC Cancer; 2010 Jan 14;10:16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PCa loses expression of CD44 standard (CD44s) that is present in benign epithelium, and overexpresses the novel splice variant isoform, CD44v7-10.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Immunol. 2000 Jan;30(1):245-53 [10602047.001]
  • [Cites] Prostate. 2009 Aug 1;69(11):1151-63 [19399788.001]
  • [Cites] Int J Cancer. 2001 Jan 1;91(1):67-75 [11149422.001]
  • [Cites] Genes Dev. 2001 Apr 15;15(8):968-80 [11316791.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10531-8 [11792695.001]
  • [Cites] J Pathol. 2002 Jun;197(2):148-54 [12015737.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):243-7 [12242156.001]
  • [Cites] Genes Dev. 2002 Dec 1;16(23):3074-86 [12464636.001]
  • [Cites] Anticancer Res. 2003 Jul-Aug;23(4):3129-40 [12926045.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):894-907 [15107804.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] J Biol Chem. 1992 Nov 5;267(31):22073-8 [1429559.001]
  • [Cites] Cancer Res. 1998 Jun 1;58(11):2350-2 [9622073.001]
  • [Cites] J Urol. 1998 Oct;160(4):1562-6 [9751413.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):219-26 [9892210.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3B):2075-83 [16158948.001]
  • [Cites] Oncol Rep. 2006 Jan;15(1):199-206 [16328056.001]
  • [Cites] Cell Death Differ. 2006 Mar;13(3):465-77 [16167069.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4B):2863-72 [16886606.001]
  • [Cites] Oncogene. 2007 Feb 8;26(6):836-50 [16953231.001]
  • [Cites] J Cell Biochem. 2007 Mar 1;100(4):1056-69 [17131386.001]
  • [Cites] Oncogene. 2007 Apr 26;26(19):2747-58 [17057731.001]
  • [Cites] Prostate. 2008 Jun 15;68(9):975-84 [18361411.001]
  • [Cites] BMC Cancer. 2008;8:260 [18793421.001]
  • [Cites] Hum Pathol. 2009 Feb;40(2):252-8 [18835619.001]
  • [Cites] Mol Cancer Res. 2009 Feb;7(2):168-79 [19208744.001]
  • [Cites] Prostate. 2009 May 15;69(7):787-98 [19189306.001]
  • [Cites] J Urol. 2000 Dec;164(6):2156-61 [11061947.001]
  • (PMID = 20074368.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / PC / PC060671
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antineoplastic Agents; 0 / Ligands; 0 / Protein Isoforms; 0 / Taxoids; 15H5577CQD / docetaxel
  • [Other-IDs] NLM/ PMC2820461
  •  go-up   go-down


65. Badr RE, Walts AE, Chung F, Bose S: BD ProEx C: a sensitive and specific marker of HPV-associated squamous lesions of the cervix. Am J Surg Pathol; 2008 Jun;32(6):899-906
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study aims to assess ProEx C expression patterns in benign, atypical, and dysplastic lesions of the cervix and to compare these patterns with p16 and Ki67 expression and with the presence of human papilloma virus DNA as determined by in situ hybridization.
  • ProEx C positivity was limited to the basal layers of the epithelium in 75% of benign cervices.
  • In the remaining 25%, staining extended into the lower half of the epithelium particularly in areas of squamous metaplasia and immature squamous metaplasia.
  • In 92% of high-grade dysplasias [cervical intraepithelial neoplasia (CIN) II and III] strong positive staining for ProEx C involved the lower and upper halves of the epithelium.
  • Condylomas and CIN I showed greater variability in staining pattern with ProEx C positivity extending into the upper half of the epithelium in 48% of cases.
  • [MeSH-major] Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / metabolism. Cell Cycle Proteins / analysis. DNA Topoisomerases, Type II / analysis. DNA-Binding Proteins / analysis. Nuclear Proteins / analysis. Papillomavirus Infections / complications. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18425044.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


66. Elayat G, Selim AG, Wells CA: Cell cycle alterations and their relationship to proliferation in apocrine adenosis of the breast. Histopathology; 2009 Feb;54(3):348-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: Apocrine adenosis (AA) is generally considered a benign disease of the breast.
  • Furthermore, proliferation in AA (4.5%) was significantly higher than that of normal breast epithelium (1%).
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / metabolism. Cell Cycle Proteins / metabolism. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19236511.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins
  •  go-up   go-down


67. Harvey AM, Grice B, Hamilton C, Truong LD, Ro JY, Ayala AG, Zhai QJ: Diagnostic utility of P504S/p63 cocktail, prostate-specific antigen, and prostatic acid phosphatase in verifying prostatic carcinoma involvement in seminal vesicles: a study of 57 cases of radical prostatectomy specimens of pathologic stage pT3b. Arch Pathol Lab Med; 2010 Jul;134(7):983-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Seminal vesicle invasion by prostatic carcinoma is directly associated with tumor staging; verification is challenging when the tumor demonstrates cribriform or papillary growth patterns or there are back-to-back small-gland proliferations.
  • P504S is overexpressed in prostatic carcinoma and high-grade prostatic intraepithelial neoplasia with cytoplasmic immunoreactivity. p63 has positive immunoreactivity in basal cell nuclei of benign prostatic glands.
  • Seminal vesicle epithelium from all 57 cases was negative for all 3 markers with distinct p63 nuclear staining of the basal cells.
  • Benign prostatic tissue was positive for PSA and PAP, as well as for p63, but negative for P504S.
  • CONCLUSIONS: The P504S/p63 one-color cocktail is a practical and cost-effective stain to differentiate prostatic carcinoma that involves the seminal vesicle from seminal vesicle epithelium.
  • It is superior to PSA or PAP when sections contain both seminal vesicle and benign glands because PSA and PAP cannot distinguish benign from malignant glands.
  • [MeSH-minor] Acid Phosphatase. Cost-Benefit Analysis. Humans. Immunohistochemistry / economics. Immunohistochemistry / standards. Male. Neoplasm Invasiveness. Neoplasm Staging. Prostate / chemistry. Prostatectomy. Staining and Labeling / economics. Staining and Labeling / standards

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20586625.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Membrane Proteins; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


68. Makarla PB, Saboorian MH, Ashfaq R, Toyooka KO, Toyooka S, Minna JD, Gazdar AF, Schorge JO: Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res; 2005 Aug 1;11(15):5365-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter hypermethylation profile of ovarian epithelial neoplasms.
  • PURPOSE: Ovarian carcinomas are believed to arise de novo from surface epithelium, but the actual molecular pathogenesis is unknown.
  • The aim of this study was to compare the promoter hypermethylation profiles of ovarian epithelial neoplasms to better understand the role of epigenetic silencing in carcinogenesis.
  • EXPERIMENTAL DESIGN: We analyzed the DNA promoter methylation status of eight tumor suppressor and cancer-related genes (p16, RARbeta, E-cadherin,H-cadherin, APC, GSTP1, MGMT, RASSF1A) in 23 benign cystadenomas, 23 low malignant potential (LMP) tumors, and 23 invasive carcinomas by methylation-specific PCR.
  • RESULTS: Benign cystadenomas exhibited promoter hypermethylation in only two genes, p16 (13%) and E-cadherin (13%).
  • LMP tumors also showed p16 (22%) and E-cadherin (17%) methylation, in addition to RARbeta (9%) and H-cadherin (4%).
  • The mean methylation index was highest in invasive tumors [0.20 versus 0.065 (LMP) and 0.033 (cystadenomas); P = 0.001].
  • Three genes exhibited higher methylation frequencies in invasive tumors: RASSF1A (30% versus 0%; P = 0.0002), H-cadherin (22% versus 2%; P = 0.013), and APC (22% versus 0%; P = 0.003).
  • CONCLUSIONS: Promoter hypermethylation is a frequent epigenetic event that occurs most commonly in invasive epithelial ovarian carcinomas.
  • The profile of aberrant methylation suggests that an accumulation of events at specific genes may trigger malignant transformation of some benign cystadenomas and LMP tumors.
  • [MeSH-major] DNA Methylation. Neoplasms, Glandular and Epithelial / genetics. Ovarian Neoplasms / genetics. Promoter Regions, Genetic
  • [MeSH-minor] Adenomatous Polyposis Coli Protein / genetics. Adult. Aged. Aged, 80 and over. Cadherins / genetics. Carcinoma / genetics. Carcinoma / pathology. Cell Transformation, Neoplastic. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Cystadenoma / genetics. DNA / metabolism. Epigenesis, Genetic. Female. Gene Silencing. Glutathione S-Transferase pi / genetics. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. O(6)-Methylguanine-DNA Methyltransferase / genetics. Polymerase Chain Reaction. Receptors, Retinoic Acid / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061849.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Cadherins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / H-cadherin; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor beta; 9007-49-2 / DNA; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi
  •  go-up   go-down


69. Zhang J, Li YL, Zhou CY, Hu YT, Chen HZ: Expression of octamer-4 in serous and mucinous ovarian carcinoma. J Clin Pathol; 2010 Oct;63(10):879-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: To assess the expression of Oct4 in epithelial ovarian tumours.
  • METHODS: Expression of Oct4 was evaluated by immunohistochemistry in 460 cases of various epithelial ovarian lesions as well as 35 cases of normal fallopian tube epithelium.
  • RESULTS: Oct4 expression was significantly increased from normal epithelium (both ovarian epithelium and fallopian tube epithelium) to benign and borderline cystadenoma to carcinoma in the serous lesion subgroup.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Cystadenoma / metabolism. Octamer Transcription Factor-3 / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Disease Progression. Epithelium / metabolism. Fallopian Tubes / metabolism. Female. Humans. Neoplasm Proteins / metabolism. Neoplasm Staging. Ovary / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20876318.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human
  •  go-up   go-down


70. Shields JA, Eagle RC Jr, Shields CL, Brown GC, Lally SE: Malignant transformation of congenital hypertrophy of the retinal pigment epithelium. Ophthalmology; 2009 Nov;116(11):2213-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of congenital hypertrophy of the retinal pigment epithelium.
  • PURPOSE: To report a clinicopathologic correlation of an adenocarcinoma that arose from solitary congenital hypertrophy of the retinal pigment epithelium (CHRPE).
  • It had features typical of CHRPE, but there was a small elevated nodule within the flat component, and the diagnosis was adenoma of the retinal pigment epithelium (RPE) arising from CHRPE.
  • Ultrasonography revealed a total retinal detachment and a pedunculated tumor measuring 7.5 mm in thickness.
  • RESULTS: Histopathologically, the mass was composed of a proliferation of atypical RPE cells with a marked infiltration of benign plasma cells.
  • Typical features of CHRPE were present at the base of the tumor.
  • CONCLUSIONS: Congenital hypertrophy of the retinal pigment epithelium, once considered to be a benign and stationary lesion, may spawn a malignant neoplasm.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Transformation, Neoplastic / pathology. Retinal Neoplasms / pathology. Retinal Pigment Epithelium / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19744732.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


71. Tan TJ, Tan TY: CT features of parotid gland oncocytomas: a study of 10 cases and literature review. AJNR Am J Neuroradiol; 2010 Sep;31(8):1413-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oncocytomas of the salivary glands are rare benign epithelial tumors which occur most commonly in the parotid gland.
  • The CT features of parotid oncocytomas in the largest imaging series of this rare but important benign lesion include a well-defined enhancing tumor with a "deformable" appearance when large, and a non-enhancing curvilinear cleft or cystic component.
  • These CT findings are potentially helpful in distinguishing these benign lesions from other parotid tumors in clinical scenarios that preclude surgical resection or when biopsy results are non-diagnostic.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20395389.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


72. Sharma V, Koirala K: Lateral rhinotomy vs mid-facial degloving for T3 inverted papilloma of nose and paranasal sinus. Nepal Med Coll J; 2009 Jun;11(2):115-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inverted papillomas are rare, benign epithelial tumours of the nasal cavity and paranasal sinuses.
  • All patients initially underwent nasal biopsy for confirmation of the diagnosis and pre-operative C.T. scan for tumour staging.
  • [MeSH-minor] Aged. Biopsy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19968152.001).
  • [Journal-full-title] Nepal Medical College journal : NMCJ
  • [ISO-abbreviation] Nepal Med Coll J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


73. Thyavihally YB, Tongaonkar HB, Desai SB: Benign mixed epithelial stromal tumor of the renal pelvis with exophytic growth: case report. Int Semin Surg Oncol; 2005 Sep 9;2:18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign mixed epithelial stromal tumor of the renal pelvis with exophytic growth: case report.
  • BACKGROUND: Mixed epithelial and stromal tumor (MEST) is a distinctive benign composite neoplasm of the kidney predominantly seen in females mostly in the perimenopausal period.
  • Although these tumors are known to arise from renal pelvis, our case was distinct in that it had no intrapelvic component growing in exophytic fashion.
  • Microscopically, the tumor was composed of large collagenized areas containing bundles of spindle cells and several 'microcysts' lined by cuboidal epithelium suggestive of a benign mixed epithelial stromal tumor.
  • DISCUSSION: Mixed epithelial tumors usually present in perimenopausal women as a partially cystic mass.
  • Tumors are composed of irregular mixtures of cystic and solid areas, glands with variable complexity and distribution and the stromal component is characterized by a spindle cell proliferation.
  • Commonly, it arises from the renal parenchyma and pelvis and nephrectomy is advocated to manage these tumors.
  • CONCLUSION: MEST is a distinctive benign tumor of the kidney that should be distinguished from other renal neoplasms.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2004 Dec;5(12):747-9 [15581546.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):958-70 [10895818.001]
  • [Cites] Hum Pathol. 2001 May;32(5):513-20 [11381370.001]
  • [Cites] Virchows Arch. 2001 Nov;439(5):700-2 [11764393.001]
  • [Cites] Semin Diagn Pathol. 1998 Feb;15(1):2-20 [9503503.001]
  • [Cites] Hinyokika Kiyo. 2004 Jan;50(1):49-52 [15032017.001]
  • [Cites] Pathologe. 2004 Sep;25(5):356-61 [15127227.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):359-67 [15322873.001]
  • [Cites] Pathol Res Pract. 1998;194(6):445-8 [9689654.001]
  • [Cites] Adv Anat Pathol. 2003 Jul;10(4):223-33 [12826829.001]
  • (PMID = 16150156.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1215508
  •  go-up   go-down


74. Guo J, Shou C, Meng L, Jiang B, Dong B, Yao L, Xie Y, Zhang J, Chen Y, Budman DR, Shi YE: Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer. Int J Cancer; 2007 Sep 15;121(6):1296-305
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Synuclein gamma (SNCG), previously identified as a breast cancer-specific gene (BCSG1), is highly expressed in breast carcinomas but not in normal epithelium.
  • Expression of SNCG was strongly correlated with the stage, lymph node involvement, metastasis, tumor size and Her-2 status, but its expression was not associated with ER and PR expression status.
  • While 71.4% of advanced breast cancers were positive for SNCG expression, only 26.8% of Stage I/II breast cancers were positive for SNCG expression and 5.2% of benign hyperplasia expressed SNCG.
  • After a median follow-up of 64 months, patients with an SNCG-positive tumor had a significantly shorter disease-free survival and overall survival and a high probability of death compared no expression of SNCG.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / metabolism. Neoplasm Proteins / metabolism. gamma-Synuclein / metabolism
  • [MeSH-minor] Amino Acid Sequence. Animals. Antibodies, Monoclonal. Blotting, Western. Disease-Free Survival. Enzyme-Linked Immunosorbent Assay. Female. Gene Expression. Humans. Immunohistochemistry. Immunoprecipitation. Kaplan-Meier Estimate. Lymphatic Metastasis. Mice. Middle Aged. Molecular Sequence Data. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17534899.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / SNCG protein, human; 0 / gamma-Synuclein
  •  go-up   go-down


75. Burghaus S, Hölsken A, Buchfelder M, Fahlbusch R, Riederer BM, Hans V, Blümcke I, Buslei R: A tumor-specific cellular environment at the brain invasion border of adamantinomatous craniopharyngiomas. Virchows Arch; 2010 Mar;456(3):287-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A tumor-specific cellular environment at the brain invasion border of adamantinomatous craniopharyngiomas.
  • Craniopharyngiomas (CP) are benign epithelial tumors of the sellar region and can be clinicopathologically distinguished into adamantinomatous (adaCP) and papillary (papCP) variants.
  • Herein, we characterized the cellular interface between the tumor and the surrounding brain tissue in 48 CP (41 adaCP and seven papCP) compared to non-neuroepithelial tumors, i.e., 12 cavernous hemangiomas, 10 meningiomas, and 14 metastases using antibodies directed against glial fibrillary acid protein (GFAP), vimentin, nestin, microtubule-associated protein 2 (MAP2) splice variants, and tenascin-C.
  • We identified a specific cell population characterized by the coexpression of nestin, MAP2, and GFAP within the invasion niche of the adamantinomatous subtype.
  • Furthermore, the outer tumor cell layer of adaCP showed a distinct expression of MAP2, a novel finding helpful in the differential diagnosis of epithelial tumors in the sellar region.
  • Our data support the hypothesis that adaCP, unlike other non-neuroepithelial tumors of the central nervous system, create a tumor-specific cellular environment at the tumor-brain junction.
  • Whether this facilitates the characteristic infiltrative growth pattern or is the consequence of an activated Wnt signaling pathway, detectable in 90% of these tumors, will need further consideration.
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Brain / metabolism. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Glial Fibrillary Acidic Protein / metabolism. Humans. Intermediate Filament Proteins / metabolism. Male. Microtubule-Associated Proteins / metabolism. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Invasiveness / physiopathology. Neoplasm Metastasis / pathology. Neoplasm Metastasis / physiopathology. Nerve Tissue Proteins / metabolism. Nestin. Tenascin / metabolism. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1595-603 [17122517.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1997-2001 [12466115.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Dec;28(6):480-8 [12445164.001]
  • [Cites] Endocr Rev. 2006 Jun;27(4):371-97 [16543382.001]
  • [Cites] J Pathol. 2004 Jul;203(3):814-21 [15221941.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 May;7(5):675-87 [17492931.001]
  • [Cites] Nat Cell Biol. 2001 Sep;3(9):778-84 [11533656.001]
  • [Cites] Brain Res. 2002 Jul 12;943(2):174-80 [12101039.001]
  • [Cites] Acta Neurochir (Wien). 2008 Dec;150(12):1213-26 [19002375.001]
  • [Cites] Oncogene. 2005 Dec 8;24(55):8200-4 [16091738.001]
  • [Cites] Glia. 2000 Feb 1;29(3):233-45 [10642750.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3897-904 [8033113.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):89-96 [15146346.001]
  • [Cites] Acta Neuropathol. 2005 Jun;109(6):589-97 [15891929.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Nov 15;139(1):9-17 [12414089.001]
  • [Cites] J Neurochem. 1999 Dec;73(6):2531-7 [10582615.001]
  • [Cites] Glia. 1997 Jan;19(1):35-46 [8989566.001]
  • [Cites] J Biol Chem. 1990 Nov 15;265(32):19679-84 [2174050.001]
  • [Cites] Neurosurgery. 2005 Apr;56(4):763-76 [15792515.001]
  • [Cites] Brain Res Dev Brain Res. 1992 Feb 21;65(2):259-67 [1373996.001]
  • [Cites] Acta Neuropathol. 1978 Sep 15;43(3):191-203 [696237.001]
  • [Cites] Brain Pathol. 2009 Jul;19(3):357-64 [18540944.001]
  • [Cites] Pediatr Neurosurg. 1996 Nov;25(5):240-6; discussion 247 [9309787.001]
  • [Cites] Brain Res Dev Brain Res. 1992 Jul 24;68(1):111-23 [1521317.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):10894-8 [7479905.001]
  • [Cites] J Cell Sci. 1994 Nov;107 ( Pt 11):3115-25 [7699010.001]
  • [Cites] Cell Tissue Res. 2003 Dec;314(3):315-24 [14523640.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Neurosurg. 2007 Jan;106(1 Suppl):3-12 [17233305.001]
  • [Cites] Matrix Biol. 2001 Feb;20(1):13-22 [11246000.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):237-50 [9950494.001]
  • [Cites] J Neurosurg. 1988 Aug;69(2):155-70 [3292716.001]
  • [Cites] Eur J Endocrinol. 2005 Apr;152(4):557-67 [15817911.001]
  • [Cites] J Neurosurg. 1990 Jul;73(1):12-7 [2352012.001]
  • [Cites] Horm Res. 2008;69(4):193-202 [18204266.001]
  • [Cites] Curr Drug Targets CNS Neurol Disord. 2005 Feb;4(1):85-92 [15723616.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):345-51 [11896213.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Apr;62(4):397-409 [15807869.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Oct;60(10):984-93 [11589429.001]
  • [Cites] Annu Rev Cell Biol. 1989;5:71-92 [2480799.001]
  • [Cites] Curr Opin Pediatr. 2007 Aug;19(4):471-9 [17630614.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Sep;82(17):6006-9 [3898077.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11771-80 [17178873.001]
  • [Cites] Glia. 1995 Apr;13(4):233-54 [7615335.001]
  • [Cites] Dev Dyn. 2004 May;230(1):1-11 [15108304.001]
  • [Cites] Brain Tumor Pathol. 2005;22(2):75-8 [18095108.001]
  • [Cites] J Neurosurg. 1998 Oct;89(4):547-51 [9761047.001]
  • [Cites] Eur J Neurosci. 2005 Oct;22(8):1863-72 [16262626.001]
  • [Cites] Pituitary. 2005;8(2):75-9 [16195780.001]
  • [Cites] Neurosurgery. 1994 Dec;35(6):1001-10; discussion 1010-1 [7885544.001]
  • [Cites] Acta Neuropathol. 2007 May;113(5):585-90 [17221204.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Mar 31;134(1-2):87-92 [11947939.001]
  • [Cites] Cell. 1990 Feb 23;60(4):585-95 [1689217.001]
  • [Cites] Exp Neurol. 1999 Dec;160(2):348-60 [10619552.001]
  • [Cites] Eur J Endocrinol. 2008 Dec;159 Suppl 1:S95-9 [18775978.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:453-4 [16700324.001]
  • [Cites] Cancer. 2003 Dec 1;98(11):2430-9 [14635078.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):206-14 [7616262.001]
  • [Cites] Neuropathology. 2007 Feb;27(1):1-9 [17319278.001]
  • (PMID = 20069432.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / Microtubule-Associated Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Tenascin; 0 / Vimentin
  •  go-up   go-down


76. Kalir T, Rahaman J, Hagopian G, Demopoulos R, Cohen C, Burstein DE: Immunohistochemical detection of glucose transporter GLUT1 in benign and malignant fallopian tube epithelia, with comparison to ovarian carcinomas. Arch Pathol Lab Med; 2005 May;129(5):651-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of glucose transporter GLUT1 in benign and malignant fallopian tube epithelia, with comparison to ovarian carcinomas.
  • CONTEXT: Enhanced expression of GLUT1, a facilitative glucose transporter found on red blood cells, blood-brain barrier, and perineurium, has been described in a large spectrum of epithelial malignancies.
  • OBJECTIVE: We present an immunohistochemical survey of GLUT1 expression in benign and malignant fallopian tube epithelia, and compare serous carcinomas of the fallopian tube and ovary.
  • DESIGN: One hundred two routinely fixed and processed archival specimens (36 benign fallopian tubes, 29 primary tubal adenocarcinomas, and 37 primary ovarian adenocarcinomas) were immunostained with rabbit anti-GLUT1 and developed with streptavidin-biotin/diaminobenzidine.
  • RESULTS: Benign tubes (n = 36) were either negatively stained (58.3%) or displayed rare weak staining (0.5+ to 1+, rarely 2+; 41.7%); of the latter, 4 specimens showed chronic salpingitis, and 6 showed hyperplasia (epithelial tufting and stratification).
  • Nineteen tubal carcinoma sections showed residual benign epithelium, which was consistently nonstaining.
  • CONCLUSIONS: GLUT1 immunostaining of fallopian tube adenocarcinomas was substantially stronger and more extensive than staining of benign tubal epithelium, consistent with previously described findings in carcinomas versus benign tissues from many primary sites.
  • [MeSH-minor] Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Glucose Transporter Type 1. Humans. Hyperplasia / metabolism. Hyperplasia / pathology. Neoplasm Staging. Precancerous Conditions / metabolism. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15859637.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / Monosaccharide Transport Proteins; 0 / SLC2A1 protein, human
  •  go-up   go-down


77. Mirza S, Bradley PJ, Acharya A, Stacey M, Jones NS: Sinonasal inverted papillomas: recurrence, and synchronous and metachronous malignancy. J Laryngol Otol; 2007 Sep;121(9):857-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Inverted papillomas are relatively rare, benign epithelial tumours of the nasal cavity which generate considerable interest because they are locally aggressive, have a tendency to recur and are associated with malignancy.
  • [MeSH-major] Neoplasm Recurrence, Local / epidemiology. Papilloma, Inverted / epidemiology. Paranasal Sinus Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17319993.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 69
  •  go-up   go-down


78. Ozbudak IH, Dertsiz L, Bassorgun CI, Ozbilim G: Giant cystic chondroid hamartoma of the lung. J Pediatr Surg; 2008 Oct;43(10):1909-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pulmonary hamartoma composed of an abnormal mixture of mesenchymal elements is the most common benign neoplasm in the lung.
  • Cystic areas and cleft-like spaces were lined by ciliated columnar epithelium.
  • [MeSH-major] Cysts / surgery. Hamartoma / surgery. Lung Diseases / surgery. Pneumonectomy / methods
  • [MeSH-minor] Adipose Tissue / pathology. Calcinosis / pathology. Calcinosis / radiography. Calcinosis / surgery. Cartilage / pathology. Child. Diagnosis, Differential. Epithelium / pathology. Humans. Incidental Findings. Lung Neoplasms / diagnosis. Male. Thoracotomy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18926231.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Kuijper A, de Vos RA, Lagendijk JH, van der Wall E, van Diest PJ: Progressive deregulation of the cell cycle with higher tumor grade in the stroma of breast phyllodes tumors. Am J Clin Pathol; 2005 May;123(5):690-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progressive deregulation of the cell cycle with higher tumor grade in the stroma of breast phyllodes tumors.
  • We studied cell cycle-regulating proteins in phyllodes tumor pathogenesis by immunohistochemical analysis for Ki-67, cyclin A, cyclin D1, retinoblastoma protein (pRb), p53, p16INK4A, bcl-2, and p21waf1 in the epithelium and stroma of 40 primary (benign, 21; borderline, 8; malignant, 11) and 7 recurrent tumors of different grades.
  • In most cases, the epithelium showed no altered expression of cell cycle regulators.
  • Stromal overexpression of p16INK4A, p53, cyclin A, pRb, and p21waf1 correlated significantly with tumor grade.
  • Stromal cyclin A expression was the best separating marker between tumor grades.
  • No immunostaining differences were detected between primary tumors and recurrences.
  • The stromal component of mammary phyllodes tumors displays an increasing level of cell cycle deregulation with higher tumor grade; the epithelial compartment mostly remains inconspicuous.
  • Several combinations of aberrantly expressed cell cycle proteins seem important in the stromal progression of phyllodes tumors.
  • [MeSH-major] Breast Neoplasms / pathology. Cell Cycle. Cell Cycle Proteins / metabolism. Phyllodes Tumor / pathology. Stromal Cells / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Female. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Proteins / metabolism. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Prognosis


80. Luo J, Peng ZL, Yang KX, Wang H, Yang H, Dong DD, Yao XY: [Relation between the expression of hypoxia inducible factor-1alpha and angiogenesis in ovarian cancer using tissue microarray]. Zhonghua Fu Chan Ke Za Zhi; 2005 Jan;40(1):38-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The expressions of HIF-1alpha mRNA, vascular endothelial growth factor (VEGF), and CD(34) in 295 patients with epithelial ovarian tumors were analyzed by tissue microarray technology, in situ hybridization and immunohistochemistry, and compared with those of 13 normal ovarian tissue samples.
  • RESULTS: The expressions of HIF-1alpha mRNA were observed in 0, 13.2%, 42.1% and 81.9% of normal ovarian tissue, benign, borderline and malignant ovarian tumors respectively.
  • Expression rates of HIF-1alpha mRNA in borderline and invasive tumors were significantly higher than those in normal ovarian tissues and benign tumors (P < 0.01).
  • Close positive relation was observed between the expression of HIF-1alpha mRNA and tumor histological grade (r = 0.246, P < 0.01).
  • [MeSH-minor] Adult. Aged. Epithelium / metabolism. Epithelium / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. RNA, Messenger / biosynthesis. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15774091.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


81. Armstrong WB, Ridgway JM, Vokes DE, Guo S, Perez J, Jackson RP, Gu M, Su J, Crumley RL, Shibuya TY, Mahmood U, Chen Z, Wong BJ: Optical coherence tomography of laryngeal cancer. Laryngoscope; 2006 Jul;116(7):1107-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This prospective study evaluated the ability of OCT to identify the characteristics of laryngeal cancer and measure changes in the basement membrane, tissue microstructure, and the transition zone at the edge of tumors.
  • Tumor and adjacent transition zones were imaged along with uninvolved subsites.
  • A transition zone to uninvolved epithelium at the tumor periphery was also often observed.
  • In six studies, benign or premalignant processes were histologically confirmed.
  • [MeSH-minor] Aged. Aged, 80 and over. Basement Membrane / ultrastructure. Biopsy. Diagnosis, Differential. Female. Humans. Laryngoscopy. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16826043.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Grant] United States / PHS HHS / / A 91717; United States / NIDCD NIH HHS / DC / DC 006026; United States / NIBIB NIH HHS / EB / EB 00293; United States / NCRR NIH HHS / RR / RR 01192; United States / NCRR NIH HHS / RR / RR00827
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


82. Scurry WC Jr, McGinn JD: Recurrent respiratory papillomatosis in pregnancy: a case of emergent airway management. Ear Nose Throat J; 2008 Jun;87(6):E8-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recurrent respiratory papillomatosis is a benign neoplastic process involving squamous epithelium of the respiratory tract, typically the vocal folds.
  • [MeSH-major] Laryngeal Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Papilloma / surgery. Pregnancy Complications, Neoplastic / surgery. Pregnancy Outcome


83. Schittenhelm J, Ebner FH, Harter P, Bornemann A: Symptomatic intraspinal oncocytic adrenocortical adenoma. Endocr Pathol; 2009;20(1):73-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most intraspinal neoplasms of epithelial origin are metastases from primary carcinomas.
  • Benign epithelial tumors are rarely found at this site.
  • The excised tumor was composed of nests of large polygonal cells with eosinophilic partial granular cytoplasm.
  • The tumor showed diffuse positivity for melan-A, synaptophysin, and alpha-inhibin.
  • Ultrastructural examination showed abundant mitochondria, suggesting an oncocytic tumor.
  • These extraadrenal tumors are thought to arise from heterotopic adrenocortical tissue in the spinal cavity.
  • Oncocytic tumors are rare neoplasms and they comprise non-functioning variants of adrenal cortical adenomas.
  • To date, only five such intraspinal tumors have been observed.
  • Immunohistochemistry excluded oncocytic paraganglioma, oncocytic meningioma, renal cell carcinoma, alveolar soft part sarcoma, and granular cell tumor.
  • A view of the literature of these rare but probably underdiagnosed intraspinal tumors is given.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Radiol. 2005 Sep;60(9):953-9 [16124976.001]
  • [Cites] Pediatr Neurosurg. 2002 May;36(5):260-5 [12053045.001]
  • [Cites] Spinal Cord. 2007 Feb;45(2):183-6 [16505829.001]
  • [Cites] Am J Surg Pathol. 1998 Jan;22(1):57-63 [9422316.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):259-64 [15306940.001]
  • [Cites] J Neurosurg. 2001 Apr;94(2 Suppl):310-2 [11302638.001]
  • [Cites] J Pediatr Surg. 1980 Jun;15(3):289-92 [6103925.001]
  • [Cites] Neurosurgery. 2006 Nov;59(5):E1144; discussion E1144 [17143207.001]
  • [Cites] Am J Surg Pathol. 1991 Oct;15(10 ):949-56 [1928551.001]
  • [Cites] Neurosurgery. 1993 Apr;32(4):658-61; discussion 661-2 [8474656.001]
  • [Cites] Histopathology. 1997 Aug;31(2):167-73 [9279569.001]
  • [Cites] Mol Cell Endocrinol. 2005 Apr 15;233(1-2):47-56 [15767045.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):375-82 [9130983.001]
  • [Cites] J Med Case Rep. 2008 Jul 13;2:228 [18620603.001]
  • [Cites] Am J Surg Pathol. 1990 May;14(5):481-4 [2327553.001]
  • [Cites] Histopathology. 1986 Mar;10(3):311-9 [2422107.001]
  • [Cites] Fetal Pediatr Pathol. 2006 Jul-Aug;25(4):191-7 [17162526.001]
  • [Cites] J Clin Pathol. 1998 Feb;51(2):114-6 [9602683.001]
  • [Cites] AMA Arch Pathol. 1959 Feb;67(2):228-33 [13616833.001]
  • [Cites] Neurosurgery. 2000 Sep;47(3):756-9 [10981764.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):231-43 [15306935.001]
  • (PMID = 19039533.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Salla C, Chatzipantelis P, Konstantinou P, Karoumpalis I, Sakellariou S, Pantazopoulou A, Manika Z: Endoscopic ultrasound-guided fine-needle aspiration cytology in the diagnosis of intraductal papillary mucinous neoplasms of the pancreas. A study of 8 cases. JOP; 2007;8(6):715-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Intraductal papillary mucinous neoplasm (IPMN) is an increasingly recognized neoplasm of the pancreas, accounting for 5% of pancreatic neoplasms, it is considered difficult to diagnose by fine-needle aspiration (FNA) cytology.
  • Mucinous epithelium was observed in all cases.
  • Two cases were diagnosed as benign IPMN and, in 3 cases, the biological behavior was not easy to determine by cytology alone (histologically diagnosed as borderline).
  • The histological diagnosis confirmed the FNA cytology diagnosis: 3 malignant IPMNs, 2 benign IPMNs and 3 borderline IPMNs.
  • Mucin 1 (MUC-1) was positive in 2 cases of malignant IPMN (histologically classified as null type ad intestinal type), mucin 2 (MUC-2) was positive in 3 cases (2 malignant both of the intestinal type, and 1 benign of the intestinal type I) and c-erbB2 was positive in 3 cases (2 benign - null and intestinal type - and 1 malignant null type).


85. Jeurnink SM, Vleggaar FP, Siersema PD: Overview of the clinical problem: facts and current issues of mucinous cystic neoplasms of the pancreas. Dig Liver Dis; 2008 Nov;40(11):837-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraductal papillary mucinous neoplasms are neoplasms with tall, columnar, mucin-containing epithelium involving the main pancreatic ducts or major side branches.
  • Serous cystic neoplasms appear as multiple cysts lined with cubic flat epithelium containing glycogen-rich cells with clear cytoplasm.
  • They mainly occur in women in their 50s and are generally benign.
  • As both mucinous cystic neoplasm and intraductal papillary mucinous neoplasms have a high malignant potential, it is important to differentiate between the various pancreatic cystic lesions.
  • Several imaging techniques and tumour markers have been evaluated.
  • A number of management issues regarding these neoplasms are still under debate, for example which imaging technique to use, differentiation between malignant or benign lesions and the preferred treatment modality for each pancreatic cystic neoplasm.
  • [MeSH-minor] Age Factors. Aged. Biomarkers, Tumor / analysis. Biopsy, Needle. Endosonography. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Pancreaticoduodenectomy / methods. Precancerous Conditions / pathology. Prognosis. Risk Assessment. Sex Factors. Survival Analysis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18499541.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen
  • [Number-of-references] 46
  •  go-up   go-down


86. Burgos San Juan L: [Cholangiocarcinoma]. Rev Med Chil; 2008 Feb;136(2):240-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cholangiocarcinoma is a malignant lesion of the bile duct epithelium.
  • It is most frequently found in the confluence of the hepatic ducts, where it is called hilar cholangiocarcinoma or Klatskin tumor.
  • Hilar cholangiocarcinoma must be distinguished from other malignant or benign causes of biliary obstruction.
  • Cholangiocarcinoma of the distal common bile duct must be differentiated from other periampullary tumors and intrahepatic cholangiocarcinoma can be confused with a hepatocellular carcinoma.
  • The type and size of surgery depends on the location and extent of the tumor.
  • Patients with unresectable tumors can be subjected to palliative procedures such as biliary-enteric bypass, endoscopic or pecutaneous stent placement.
  • [MeSH-minor] Humans. Neoplasm Staging / methods

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18483680.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Chile
  • [Number-of-references] 43
  •  go-up   go-down


87. Tan PH, Jayabaskar T, Yip G, Tan Y, Hilmy M, Selvarajan S, Bay BH: p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study. Mod Pathol; 2005 Dec;18(12):1527-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study.
  • Breast phyllodes tumors are fibroepithelial neoplasms whose clinical behavior is difficult to predict on histology.
  • In this study, we determined if p53 and CD117 (c-kit) protein expression was predictive of behavior in a series of 335 phyllodes tumors diagnosed at the Singapore General Hospital, using immunohistochemistry on tissue microarrays.
  • Representative areas from 250 (75%) benign, 54 (16%) borderline and 31 (9%) malignant phyllodes tumors were selected for construction of tissue microarrays using the 2 mm punch.
  • Staining proportion and intensity of both epithelial and stromal elements were analyzed. p53 immunostaining was observed in the epithelium of 28 (10%) of 278 microarrays; myoepithelium of 53 (21%) of 251 microarrays; and stromal cells in 105 (36%) of 289 microarrays.
  • CD117 immunohistochemical reactivity was noted in epithelial and stromal components of 175 (of 267, 66%) and 17 (of 273, 6%) microarrays, respectively.
  • Stromal p53 and CD117 protein expression was associated with tumor grade (P < 0.05).
  • We conclude that tissue microarrays are a convenient method for evaluating immunostaining results of large numbers of phyllodes tumors.
  • Although positive p53 stromal immunohistochemical detection may corroborate histologic malignancy, it is CD117 protein expression in phyllodes tumor stromal cells that may be of potential utility in predicting recurrent disease.
  • [MeSH-major] Breast Neoplasms / diagnosis. Phyllodes Tumor / diagnosis. Proto-Oncogene Proteins c-kit / metabolism. Tissue Array Analysis / methods. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Recurrence, Local. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258510.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


88. Turley RS, Finger EC, Hempel N, How T, Fields TA, Blobe GC: The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res; 2007 Feb 1;67(3):1090-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer.
  • The transforming growth factor-beta (TGF-beta) signaling pathway has an important role in regulating normal prostate epithelium, inhibiting proliferation, differentiation, and both androgen deprivation-induced and androgen-independent apoptosis.
  • Here, we show that type III TGF-beta receptor (TbetaRIII or betaglycan) expression is decreased or lost in the majority of human prostate cancers as compared with benign prostate tissue at both the mRNA and protein level.
  • Loss of TbetaRIII expression correlates with advancing tumor stage and a higher probability of prostate-specific antigen (PSA) recurrence, suggesting a role in prostate cancer progression.
  • [MeSH-major] Genes, Tumor Suppressor. Prostatic Neoplasms / genetics. Proteoglycans / genetics. Receptors, Transforming Growth Factor beta / genetics
  • [MeSH-minor] Animals. Cell Growth Processes / genetics. Cell Line, Tumor. Cell Movement / genetics. Humans. Loss of Heterozygosity. Male. Mice. Mice, Inbred BALB C. Neoplasm Invasiveness. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17283142.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 106307
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proteoglycans; 0 / Receptors, Transforming Growth Factor beta; 145170-29-2 / betaglycan
  •  go-up   go-down


89. Barbarino S, McCormick SA, Lauer SA, Milman T: Syringocystadenoma papilliferum of the eyelid. Ophthal Plast Reconstr Surg; 2009 May-Jun;25(3):185-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To describe 6 patients with syringocystadenoma papilliferum of the eyelid and to review the literature regarding this rare eyelid tumor.
  • These channels were lined by nonkeratinizing epithelium and communicated with the epidermis.
  • Nine lesions (64%) were associated with apocrine, eccrine, or sebaceous tumors or malformations.
  • None of the lesions was associated with a malignant neoplasm.
  • Although syringocystadenoma papilliferum of the eyelid can be associated with other benign lesions, no malignant transformation or association with malignant neoplasms has been reported.
  • The evidence suggests that this tumor should be managed with conservative complete excision.

  • Genetic Alliance. consumer health - Syringocystadenoma papilliferum.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19454927.001).
  • [ISSN] 1537-2677
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 12
  •  go-up   go-down


90. Walton TJ, Li G, McCulloch TA, Seth R, Powe DG, Bishop MC, Rees RC: Quantitative RT-PCR analysis of estrogen receptor gene expression in laser microdissected prostate cancer tissue. Prostate; 2009 Jun 1;69(8):810-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Fresh tissue was obtained from 11 radical prostatectomy specimens and from 6 patients with benign prostate hyperplasia.
  • Pure populations of benign and malignant prostate epithelium were laser microdissected, followed by RNA isolation and electrophoresis.
  • ERbeta gene expression was significantly over-expressed in the cancer group compared with benign controls (P < 0.01).
  • [MeSH-minor] DNA Primers. DNA, Neoplasm / genetics. Estrogen Receptor alpha / genetics. Humans. Lasers. Male. Microdissection. Polymerase Chain Reaction. Prostate / physiology. Prostate-Specific Antigen / genetics. Prostatectomy. RNA, Neoplasm / genetics. RNA, Neoplasm / isolation & purification. Receptors, Androgen / genetics. Receptors, Progesterone / genetics. Reference Values. Reverse Transcriptase Polymerase Chain Reaction. Transcription, Genetic

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19189301.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Neoplasm; 0 / Estrogen Receptor alpha; 0 / RNA, Neoplasm; 0 / Receptors, Androgen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


91. Zhao XY, Schneider D, Biroc SL, Parry R, Alicke B, Toy P, Xuan JA, Sakamoto C, Wada K, Schulze M, Müller-Tiemann B, Parry G, Dinter H: Targeting tomoregulin for radioimmunotherapy of prostate cancer. Cancer Res; 2005 Apr 1;65(7):2846-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, radioimmunotherapy should still be efficacious in metastatic prostate cancer as radioisotopes are brought to tumor cells by targeting antibodies.
  • Immunohistochemical studies of tomoregulin protein in clinical samples show its location in the luminal epithelium of normal prostate, benign prostatic hyperplasia, and prostatic intraepithelial neoplasia.
  • More importantly, the tomoregulin protein is expressed in primary prostate tumors and in their lymph node and bone metastases.
  • The nature of tomoregulin as a transmembrane protein and its tissue-specific expression make tomoregulin an attractive target for radioimmunotherapy, in which tomoregulin-specific antibodies will deliver a radioisotope to prostate tumor cells and metastases.
  • Indeed, biodistribution studies using a prostate tumor xenograft model showed that the (111)In-labeled anti-tomoregulin antibody 2H8 specifically recognizes tomoregulin protein in vivo, leading to a strong tumor-specific accumulation of the antibody.
  • In efficacy studies, a single i.p. dose of 150 microCi (163 microg) (90)Y-labeled 2H8 substantially inhibits the growth rate of established LNCaP human prostate tumor xenograft in nude mice but produces no overt toxicity despite cross-reactivity of 2H8 with mouse tomoregulin.
  • [MeSH-major] Immunotoxins / therapeutic use. Indium Radioisotopes / therapeutic use. Membrane Proteins / biosynthesis. Neoplasm Proteins / biosynthesis. Prostatic Neoplasms / radiotherapy. Radioisotopes / therapeutic use. Ytterbium / therapeutic use
  • [MeSH-minor] Animals. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / pharmacokinetics. Antibodies, Monoclonal / therapeutic use. Brain / metabolism. Cell Line, Tumor. Humans. Immunoglobulin G / immunology. Immunoglobulin G / metabolism. Male. Mice. Mice, Nude. Neoplasm Metastasis. Prostate / metabolism. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Radioimmunotherapy. Radiopharmaceuticals / immunology. Radiopharmaceuticals / pharmacokinetics. Radiopharmaceuticals / therapeutic use. Tissue Distribution. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15805286.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunoglobulin G; 0 / Immunotoxins; 0 / Indium Radioisotopes; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Radioisotopes; 0 / Radiopharmaceuticals; 0 / TMEFF2 protein, human; MNQ4O4WSI1 / Ytterbium
  •  go-up   go-down


92. Gopalan A, Sharp DS, Fine SW, Tickoo SK, Herr HW, Reuter VE, Olgac S: Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation. Am J Surg Pathol; 2009 May;33(5):659-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Urachal carcinomas occur mostly in the bladder dome, comprising 22% to 35% of vesical adenocarcinomas, and are generally treated by partial cystectomy with en bloc resection of the median umbilical ligament and umbilicus.
  • DESIGN: We reviewed histologic material and clinical data from 24 cases selected from a database of 67 dome-based tumors diagnosed and treated at our institution from 1984 to 2005.
  • In all instances but 1, cystitis cystica/glandularis was focal and predominantly in the bladder overlying the urachal neoplasm.
  • Urachal remnants were identified in 15 cases: the urachal epithelium was benign urothelial-type in 6 cases and showed adenomatous changes in 9.
  • In all 3, urachal remnants were identified and showed transition from benign to adenomatous epithelium.
  • On immunohistochemistry, these tumors were positive for CK20 and variably positive for CK7 and 34BE12.
  • Local recurrence may be owing to seeding within the distal urothelial tract, particularly in tumors with a configuration that is polypoid and which open into the bladder cavity.
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Signet Ring Cell / pathology. Chemotherapy, Adjuvant. Cystectomy. Cystitis / pathology. Databases as Topic. Female. Homeodomain Proteins / analysis. Humans. Immunohistochemistry. Keratin-20 / analysis. Keratin-7 / analysis. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy, Adjuvant. Treatment Outcome. Umbilicus / surgery. beta Catenin / analysis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1380-7 [11684954.001]
  • [Cites] Cancer. 2007 Dec 1;110(11):2434-40 [17932892.001]
  • [Cites] J Urol. 2003 Apr;169(4):1295-8 [12629346.001]
  • [Cites] Arch Pathol Lab Med. 2004 Apr;128(4):456-9 [15043458.001]
  • [Cites] J Urol. 1982 Jan;127(1):40-2 [7057501.001]
  • [Cites] Urology. 1983 Apr;21(4):360-6 [6836822.001]
  • [Cites] J Urol. 1984 Jan;131(1):1-8 [6361280.001]
  • [Cites] Urol Res. 1983;11(5):235-8 [6659216.001]
  • [Cites] Urology. 1985 Sep;26(3):218-21 [4035835.001]
  • [Cites] J Urol. 1986 Jun;135(6):1240-4 [3712579.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2165-72 [1706216.001]
  • [Cites] J Urol. 1994 Feb;151(2):365-6 [8283526.001]
  • [Cites] Hum Pathol. 1996 Mar;27(3):240-7 [8600037.001]
  • [Cites] Cancer. 1955 Jul-Aug;8(4):741-58 [13240656.001]
  • [Cites] Mod Pathol. 2005 Sep;18(9):1217-22 [15803184.001]
  • [Cites] Semin Diagn Pathol. 2005 Feb;22(1):69-87 [16512600.001]
  • [Cites] J Urol. 2006 Jun;175(6):2042-7; discussion 2047 [16697798.001]
  • [Cites] Cancer. 2006 Aug 15;107(4):712-20 [16826585.001]
  • [Cites] Cancer. 2006 Aug 15;107(4):721-8 [16826584.001]
  • [Cites] J Urol. 2007 Jul;178(1):74-8; discussion 78 [17499279.001]
  • [Cites] Histopathology. 2002 May;40(5):403-39 [12010363.001]
  • (PMID = 19252435.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA082088
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / CTNNB1 protein, human; 0 / Homeodomain Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / beta Catenin
  • [Other-IDs] NLM/ NIHMS627175; NLM/ PMC4225778
  •  go-up   go-down


93. Halbritter SA, Altermatt HJ, Caversaccio M, Bornstein MM: Apocrine papillary cystadenoma of a minor salivary gland on the lower lip: case presentation. Quintessence Int; 2009 Feb;40(2):167-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystadenomas are a rare, painless, and slow-growing benign epithelial tumor of the salivary gland.

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19169449.001).
  • [ISSN] 1936-7163
  • [Journal-full-title] Quintessence international (Berlin, Germany : 1985)
  • [ISO-abbreviation] Quintessence Int
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


94. Kovalenko S, Lukashenko P, Romanovskaya A, Soldatski IL, Bakanov SI, Pfister H, Gerein V: Distribution and density of CD1a+ and CD83+ dendritic cells in HPV-associated laryngeal papillomas. Int J Pediatr Otorhinolaryngol; 2009 Feb;73(2):249-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Respiratory papillomatosis associated with human papilloma virus (HPV) infection is the most common benign laryngeal neoplasm.
  • The correlation between dendritic cell (DC) density in tumor tissue and clinical prognosis was established.
  • The density of DC was analysed in epithelial layer and lamina propria.
  • RESULTS: In the epithelial layer of papillomas the number of CD1a+ and CD83+ DC was 86.2 (47.5-119.9) cells/mm(2) and 2.6 (0.6-7.9) cells/mm(2), respectively.
  • For subgroups of patients with high number of operations (more than 3), early disease onset (children under 3 years of age) and lingering duration of disease (more than 1 year) we detected an increase of CD83+ DC in the epithelial layer.
  • However, our data did not demonstrate a statistically significant difference in CD1a+ DC count neither in the epithelium nor in the lamina propria.
  • Probably, the increase of CD83+ DC density in epithelial layer of patients with severe course of disease can be an evidence of impaired migration of matured DC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19062106.001).
  • [ISSN] 0165-5876
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD1; 0 / CD1a antigen; 0 / CD83 antigen; 0 / Immunoglobulins; 0 / Membrane Glycoproteins
  •  go-up   go-down


95. Chung EM, Cube R, Lewis RB, Conran RM: From the archives of the AFIP: Pediatric liver masses: radiologic-pathologic correlation part 1. Benign tumors. Radiographics; 2010 May;30(3):801-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From the archives of the AFIP: Pediatric liver masses: radiologic-pathologic correlation part 1. Benign tumors.
  • Benign hepatic tumors in children include lesions that are unique to the pediatric age group and others that are more common in adults.
  • Infantile hemangioendothelioma, or infantile hepatic hemangioma, is a benign vascular tumor that may cause serious clinical complications.
  • The mesenchymal component or cystic component may predominate; this predominance determines the imaging appearance of the tumor.
  • Benign epithelial tumors that are common in adults may infrequently occur in childhood.
  • Knowledge of how the pathologic features of these tumors affect their imaging appearances helps radiologists offer an appropriate differential diagnosis and management plan.

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20462995.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Wang WB, Li YH, Liu B, Wang HS, Cui AR, Zhnag XH: [Correlation between PPARgamma and VEGF-C expression in extrahepatic cholangioadenocarcinoma (EHCAC) and their prognostic significance]. Zhonghua Zhong Liu Za Zhi; 2009 Oct;31(10):773-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The expressions of PPARgamma and VEGF-C were detected by immunohistochemistry in 69 cases of EHCAC, 12 cases of non-tumor bile duct epithelium, and their relationship to clinicopathological parameters and follow-up were analyzed.
  • RESULTS: The positive rate of PPARgamma expression in 69 cases of EHCAC was 59.4%, significantly higher than that in 12 cases of non-tumor bile duct epithelium (0%), (P < 0.01).
  • The positive rate of VEGF-C in 69 cases of EHCAC was 84.1%, also significantly higher than 16.7% in 12 cases of benign bile duct epithelium (P < 0.05).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Survival Rate

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021832.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / PPAR gamma; 0 / VEGFC protein, human; 0 / Vascular Endothelial Growth Factor C
  •  go-up   go-down


97. Ota T, Gilks CB, Longacre T, Leung PC, Auersperg N: HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features. Reprod Sci; 2007 Sep;14(6):605-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.
  • Interrelationships between HOXA7 expression and ovarian cancer progression are investigated by cDNA array and by immunohistochemistry of normal ovaries and 538 epithelial ovarian tumor microarrays.
  • HOXA7 mRNA expression was higher in carcinomas than in benign tumors.
  • HOXA7 protein was absent in normal surface epithelium but appeared in metaplastic regions.
  • There were significant associations of strong HOXA7 staining of stroma and tumor nuclei with the clear cell histotype (stroma: P = .0022, nuclei: P = .0003) and of weak/absent staining with serous carcinomas.
  • Tumor E-cadherin expression correlated significantly with HOX7 staining in stroma (P = .0002) but not within tumors.
  • HOXA7 staining of tumor cell nuclei is correlated significantly with improved disease-specific survival (P = .0104), which is suggestive of the biological and potentially clinical importance of subcellular HOXA7 localization.
  • [MeSH-major] Adenocarcinoma, Clear Cell / chemistry. Adenocarcinoma, Mucinous / chemistry. Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / chemistry. Cell Differentiation. Cystadenocarcinoma, Serous / chemistry. Homeodomain Proteins / analysis. Ovarian Neoplasms / chemistry
  • [MeSH-minor] Cadherins / analysis. Cell Nucleus / chemistry. Cluster Analysis. Female. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Metaplasia. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Prognosis. Stromal Cells / chemistry. Stromal Cells / pathology. Tissue Array Analysis


98. Bhalla RK, Wright ED: Predicting the site of attachment of sinonasal inverted papilloma. Rhinology; 2009 Dec;47(4):345-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STATEMENT OF PROBLEM: Sinonasal inverted papilloma is a benign, epithelial neoplasm, which has a propensity for malignant transformation and recurrence.
  • The evolution of endoscopic trans-nasal surgery has facilitated less destructive and, more functionally and cosmetically acceptable approaches to this tumour.
  • Precise surgery is enhanced by pre-operative localisation of the site of tumour attachment.
  • Intra-operatively, the actual site of tumour attachment was established.
  • A correlation between the predicted and actual site of tumour attachment was calculated.

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19936356.001).
  • [ISSN] 0300-0729
  • [Journal-full-title] Rhinology
  • [ISO-abbreviation] Rhinology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


99. Calcaterra R, Franco G, Valenzano M, Fazio R, Morrone A: Clinical features and treatment of dermatosis papulosa nigra in migrants to Italy. Skinmed; 2010 Jul-Aug;8(4):207-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dermatosis papulosa nigra (DPN) is a benign epithelial tumor that is common in dark-skinned people.
  • Therefore, even if DPN is a benign disease, the lesions are unaesthetic and the therapeutic options are quite inefficient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21137605.001).
  • [ISSN] 1540-9740
  • [Journal-full-title] Skinmed
  • [ISO-abbreviation] Skinmed
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Miot HA, Miot LD, da Costa AL, Matsuo CY, Stolf HO, Marques ME: Association between solitary keratoacanthoma and cigarette smoking: a case-control study. Dermatol Online J; 2006;12(2):2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Solitary keratoacanthoma (KA) is a common benign epithelial tumor of the skin characterized by rapid growth and a tendency toward spontaneous regression.
  • The exact etiology and classification of KA are a matter of debate.

  • Genetic Alliance. consumer health - Keratoacanthoma.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16638395.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement